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ABSTRACT
Overexpression of a fusion between the GAL4 DNA binding domain and
the powerful VP16 activation domain is toxic to yeast. ADA2and ADA3 were
isolated in a selection for mutants resistant to GAL4-VP16 toxicity. ada2 and
ada3 mutants grow slowly on minimal medium, are temperature sensitive, and
cannot support activation by certain activation domains in vivo and in vitro. This
last property suggests that ADA2 and ADA3 function as transcriptional adaptors
to mediate the interaction of activation domains and basal factors.
In the initial selection, only 2 alleles of ada2, and one allele of ada3 were
isolated, suggesting that the selection was not saturated. Here, I report the
isolation and characterization of two additional genes, GCN5 and ADA5 in the
toxicity selection. gcn5 mutants are phenotypically similar to ada2 and ada3
mutants. ada2gcn5 or ada3gcn5 double deletion mutants grow no more slowly
than single deletion mutants, arguing that these genes are in the same pathway
or complex. In fact, GCN5 can bind ADA2 in vivo and in vitro, forms a complex
with ADA2 and ADA3 in vitro, and copurifies with ADA2 and ADA3 from yeast
extracts.
ADA5, on the other hand, is in a phenotypically different class from the
ADA2 complex genes. ada5 mutants grow more slowly than ada2 mutants, and
have more general activation defects. Genetic evidence suggests ADA5 works
in the same pathway as ADA2, but ADA5 does not copurify with the ADA2
complex. Finally, ADA5 can bind directly to the VP16 activation domain, and is
identical to SPT20, a gene that may regulate the binding of TBP to promoters in
vivo. This suggests that ADA5 may function as an adaptor by contacting
activation domains, and regulating the binding of TBP to promoters.
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Overview: Transcription requires activators and basal factors
An RNA Polymerase II promoter has at least two different kinds of cis
acting elements, a proximal element, often a TATA box, and a distal enhancer
or UAS element. Activation requires three different classes of transcription
factors: basal factors, activators, and coactivators. The basal factors, such as
RNA polymerase, assemble at the TATA box. Activators are sequence specific
DNA binding proteins or complexes that recognize UAS/enhancer elements
and interact directly or indirectly with the basal transcription factors at the TATA
box to promote transcriptional initiation. Coactivators are necessary for
activated but not basal transcription. Transcriptional adaptors are one class of
coactivators that bind activators and basal factors to mediate activation. In order
to understand the mechanism of activation, we must first understand basal
factors, activators and coactivators.
Basal Factors
It is possible to reconstitute transcription that accurately initiates at a
TATA box in vitro. Purification of cell extracts has identified eight fractions
designated TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, TFIIJ and RNA polymerase II
can be used to reconstitute not only basal, but also activated transcription
(Conway and Conway, 1993; Zawel and Reinberg, 1993). Many of these
factors are now available as recombinant proteins or as highly purified fractions
(Buratowski, 1994).
TFIID is the only basal factor that can bind the TATA box in a sequence
specific manner, and thus promoter recognition and binding by TFIID is the first
step in transcriptional initiation in most models (Buratowski, 1994). It is
important to note that TFIID is a complex that can be separated into two distinct
activities. TBP, the TATA binding protein.is capable of binding to the TATA box
alone and is sufficient for basal but not activated transcription (Pugh and Tjian,
1990). The TAFs (IBP-associated factors) are tightly associated with TBP and
are necessary for activated but not basal transcription (Dynlacht, et al., 1991).
A preinitiation complex can be assembled by ordered addition of basal
factors to template DNA (Buratowski, et al., 1989). In the first step, TBP binds
the TATA box. TBP binding is stabilized by the binding of TFIIA. TFIIB can bind
to TBP in the presence or absence of TFIIA, although the TBPITFIIA/TFIIB (DAB)
complex is more stable than the TBP/TFIIB (DB) complex. The DB or DAB
complex recruits RNA polymerase, which pre-assembles with TFIIF. TFIIF is
thought to stabilize the TFIIB-polymerase interaction. Finally, TFIIE and TFIIH
are recruited to the complex sequentially (reviewed in Buratowski, 1994;
Conway and Conway, 1993; Zawel and Reinberg, 1993).
It is also possible to assemble mini-complexes that have only a fraction of
the activity of the complete preinitiation complex. For example, on certain
negatively supercoiled templates, TBP, TFIIB, TFIIF and RNA polymerase II are
sufficient for transcriptional initiation (Parvin, et al., 1994). In fact, for one
template, TFIIF is dispensable. For initiation complexes using this mini-
complex, the level of transcription is correlated with the number of negative
supercoils, suggesting that the supercoils may be providing a source of energy
to drive the transcription process (Parvin, et al., 1994).
The TBP/TFIIB/TFIIF/polymerase mini-complex cannot transcribe linear
templates, although it can produce abortive (three nucleotide) RNAs (Goodrich
and Tjian, 1994; Parvin, et al., 1994). This suggests that on linear templates,
transcription by this minicomplex is blocked after RNA synthesis begins, but
very early in its synthesis. This theoretical stage, called promoter clearance
which proceeds on negatively supercoiled DNA templates can occur on linear
templates only if TFIIE, TFIIH and ATP are included in the initiation complex
(Goodrich and Tjian, 1994). This suggests that TFIIE and TFIIH play a role in
promoter clearance (Goodrich and Tjian, 1994). However, others suggest that
the abortive initiation assay may be an artifact, and that TFIIH plays a role in
open complex formation (R. Young and P. Sharp, personal communication).
During the transition from an initiation to an elongation complex, the
carboxy terminal domain (CTD) of RNA polymerase is phosphorylated
(Laybourn and Dahmus, 1990). The CTD is a highly conserved structure
consisting of a heptapeptide sequence that is repeated 26 times in yeast RPB1
and 52 times in human RPB1 and is essential for viability (Young, 1991). The
phosphorilation of the CTD may help distinguish elongating polymerase from
initiating polymerase because polymerase with an unphosphorylated CTD
preferentially binds to initiation complexes (Lu, et al., 1991), and polymerase
with a phosphorylated CTD is isolated from elongating transcription complexes
(Payne, et al., 1989). Several kinases, including the M015 subunit of TFIIH are
capable of phosphorilating the CTD (Serizawa, et al., 1995). However, the
significance of CTD phosphorylation is not entirely understood. Polymerase
with an unphosphorylated CTD shows normal transcriptional initiation and
elongation in vitro (MAlaka, et al., 1995). Finally, analysis of CTD truncation
mutants in vitro suggests that the CTD functions in the response to
transcriptional activators, and does not influence elongation (Liao, et al., 1991).
Genetic analysis of basal factors in yeast suggests additional properties
of basal factors not necessarily identified by biochemical experiments in vitro.
For example, mutants in SUA7which encodes yeast TFIIB show altered start
site selection (Pinto, et al., 1992), an activity not apparent in the biochemical
analysis of TFIIB. Further, it is important whenever possible to confirm that a
basal factor has a given activity in vivo. To this end, CTD truncation mutants
have demonstrated that the CTD is necessary for viability, and may mediate the
response to some activators. Progressive CTD truncations result in first
temperature/cold sensitivity and then inviability (Nonet, et al., 1989). The
conditional mutants are also inositol auxotrophs which results from decreased
expression of the INO1 gene (Scafe, et al., 1990).
TBP mutants have also been extensively studied in vivo. Several of
these confirm the importance of TBP properties described in vitro. Mutants
inspt15, which encodes the yeast TBP were isolated as suppressors of Ty
insertions in yeast promoters (Eisenmann, et al., 1989; Hahn, et al., 1989).
Some of these have altered DNA binding specificity in vitro, and show altered
promoter selection for transcriptional initiation in vivo, confirming that promoter
selection can indeed be mediated by TBP (Arndt, et al., 1992). A TBP mutant
unable to bind TFIIA is able to support constitutive but not activated transcription
in vivo (Stargell and Struhl, 1995). This suggests that the TFIIA-TBP interaction
is critical for activation in vivo (Stargell and Struhl, 1995). Other TBP mutants
will be cited later to illustrate how TBP responds to activators.
Transcriptional activators
Transcriptional activators have been biochemically or genetically shown
to be sequence specific DNA binding proteins that bind to UAS or enhancer
elements and promote activation. Initial characterization of transcriptional
activators showed that they are modular in nature, with separable activation and
DNA binding domains (Hope and Struhl, 1986). Since then, the complex
nature of the transcriptional activator has been further unraveled, such that
domains for DNA binding, activation, dimerization, and cofactor binding (e.g.
hormone receptors) have been identified. Each of these can make important
contributions to the activation process. For example, the DNA binding
specificity of an activator, or its ability to activate, can vary with its dimerization
partner.
In addition, there is growing evidence that DNA binding domains play a
role in activation beyond tethering an activation domain to a specific DNA
sequence. The existence of positive control mutants in DNA binding domains
that do not alter DNA binding but reduce activation suggests that the DNA
binding domain makes specific contacts with cofactors necessary for activated
transcription (Turcotte and Guarente, 1992). In fact, one putative coactivator,
TAF55, has been shown to bind to the SP1 DNA binding domain (Chiang and
Roeder, 1995).
Activation domains were initially characterized by their amino acid
content. Acidic, Glutamine rich, Serine/Threonine rich, Proline rich and
Isoleucine rich activation domains have been described (Triezenberg, 1995).
Only acidic activation domains activate in yeast, suggesting that the coactivators
for these other types of activation domains are present only in Metazoans.
Recent analysis of activation domains suggests that characterization of
activation domains by amino acid content is an oversimplification in two ways.
First, although acidic and glutamine residues characterize the VP16 and SP1
activation domains respectively, individual acidic or glutamine residues to not
make essential contributions to trans-activation (Cress and Triezenberg, 1991;
Gill, et al., 1994). In fact, it is large bulky hydrophobic amino acids that are the
critical residues within an activation domain (Cress and Triezenberg, 1991;
Drysdale, et al., 1995; Gill, et al., 1994). Second, two activation domains that
appear similar by amino acid composition often behave differently in activation
assays. For example in yeast, the acidic activation domains GCN4 requires the
transcriptional adaptor ADA2 in order to activate, whereas the HAP4 acidic
activation domain activates in an ADA2 independent manner (Pifia, et al.,
1993). Similarly, different glutamine rich activation domains show variable
abilities to interact with the coactivator TAF110 (Hoey, et al., 1993).
Additionally, activation domains themselves are modular and can be
subdivided into smaller units that themselves have the ability to activate
transcription (Drysdale, et al., 1995; Seipel, 1992; Silverman, et al., 1994). In
some cases, these units appear to have different specificities, and may trans-
activate by different mechanisms (Silverman, et al., 1994). These issues might
be resolved if the structure of activation domains were known. However,
several studies have failed to find any discernible structure in an activation
domain, which suggests that activation domains may adopt a structure by
induced fit when they bind their targets (Triezenberg, 1995).
Activators activate by several pathways. Activators can counteract
nucleosomal repression, and influence the activity of basal factors in vivo.
Some models to explain the mechanism of activation have suggested that direct
interactions between activation domains and basal factors as one component.
In addition, proteins called coactivators or transcriptional adaptors have been
discovered that are necessary for activated but not basal transcription. In the
following sections, I will discuss experiments that relate to chromatin anti-
repression, the response of TBP to activators in vivo, direct interactions between
activators and basal factors, and the discovery of coactivators.
Activators counter nucleosomal repression
Complete nucleosomes or Histone H1 alone can repress transcription in
vitro (Grunstein, et al., 1992). The repressive effects of histone H1 or
nucleosomes can be overcome by transcriptional activators (Croston and
Kadonaga, 1993; Workman, et al., 1991). Thus, one function of activators is to
alleviate repression by chromatin. Furthermore, genetic evidence in yeast
suggests that histones regulate transcriptional activation in vivo (Grunstein, et
al., 1992). For example, repressing the synthesis of certain histones results in
elevated expression of some yeast genes (Han, 1989). In addition, the non-
conserved N-terminal arms of histones H3 and histone H4 are required for
transcriptional repression and transcriptional activation respectively of the
GALl-10 genes in vivo (Durrin, et al., 1991; Mann and Grunstein, 1992).
Similarly, different mutations the gene encoding histone H2A can cause
positive or negative changes in the transcription of the SUC2 gene (Hirschhorn,
et al., 1995; Hirschhorn, et al., 1992). However, anti-repression cannot account
for the total effect of trans-activation (Wolffe, 1994). Moreover, activated
transcription can occur on "naked DNA" in vitro in the absence of histones, and
thus must involve a more direct regulation of basal factors.
TBP responds to activators in vivo
Mutant analysis suggests that one way activators function in vivo is to
regulate TBP binding to the TATA box. For example, some mutants in TBP that
display lower affinity for the TATA box in vitro, show activation defects in vivo
(Arndt, et al., 1995). Importantly, the activation defects are not governed by the
TATA box but by the activator, suggesting that binding of TBP to some
promoters may be regulated by activators (Arndt, et al., 1995). If TBP is tethered
to DNA by a DNA binding domain, it can interact with the TATA element and
activate transcription without an upstream activator (Chatterjee and Struhl,
1995; Klages and Strubin, 1995; Xiao, et al., 1995). Thus, decreasing TBP
binding can result in activator dependent transcription decreases, and
increasing TBP DNA binding by tethering it to DNA allows activation without
activators. Together, these results suggest TBP binding to the TATA box can be
regulated by activators. Moreover, there are human TBP mutants that show
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activator specific transcription defects in vivo. This activator specificity suggests
that in vivo, TBP responds to different activators in different ways (Arndt, et al.,
1995; Tansey, et al., 1994).
Direct interactions between activation domains and basal factors in
vitro
Clearly, activators operate by countering nucleosomal repression, and
influencing basal factors. Mechanistically, activation domains presumably
operate through protein-protein interactions with other members of the
transcriptional apparatus. By identifying the target or targets of activation
domains, we will begin to unravel the mechanism of its action. The basal
transcription factors represent one obvious target for activation domains, and in
fact several basal factors have been shown to interact directly with activation
domains.
TBP was the first basal factor that was shown to bind directly to an
activation domain (Stringer, et al., 1990). Since the binding of TBP or TFIID to
the TATA box is the first step in activation, and may be limited or regulated in
vivo, there is a good rational for a direct interaction between TBP and an
activation domain (Triezenberg, 1995). The interaction between TBP and
VP16, a well studied, powerful activation domain, is sensitive to mutations in
VP16 that reduce its ability to trans-activate (Ingles, et al., 1991). In addition,
TBP mutants have been isolated that can support basal but not activated
transcription (Kim, et al., 1994a; Tansey, et al., 1994). One of these is no longer
able to bind directly to VP16, suggesting that VP16 TBP interactions may
indeed play a role in activated transcription (Kim, et al., 1994a). However,
there is no evidence whether direct interactions between VP16 and TBP
facilitate activated transcription in vivo.
VP16 has also been shown to interact directly with TFIIB (Lin, 1991; Lin,
et al., 1991). As was the case with TBP, this interaction is also sensitive to
mutations in the VP16 activation domain (Lin, et al., 1991). Moreover, double
point mutants within a domain of TFIIB argue that direct interactions are indeed
important for activation. These double mutants only weakly bind VP16, and
support basal but not activated transcription (Roberts, 1993). In addition, VP16
induces a conformational change in TFIIB that may expose a site within TFIIB
that binds basal factor(s), facilitating the assembly of the initiation complex
(Roberts and Green, 1994).
Additionally, the VP16 and p53 activation domains can bind to the basal
factor TFIIH through its p62 subunit (Xiao, et al., 1994). The strength of the
VP16 TFIIH interaction correlates with the ability of VP16 to activate
transcription. Mutants that reduce the ability of VP16 to activate also reduce its
binding to TFIIH (Xiao, et al., 1994). TFIIH has several properties that make it an
interesting target for activation domains. First, TFIIH contains helicase and
kinase activities that could potentially be regulated by activators. However,
activation domains have not been shown to alter either of these activities, and
these activities have not yet been shown to be important for transcription.
Second, TFIIH acts in promoter clearance (Goodrich and Tjian, 1994), which is
after the stages in transcription where TBP and TFIIB first operate. This
suggests that activation domains could function at several stages in activation
by contacting basal factors that operate in different stages of transcription.
Finally, the artificial activation domain AH or VP16 can recruit TFIIB into
preinitiation complexes (Choy and Green, 1993; Lin, 1991). In fact, in one
system, the activation domain appears to be acting twice in transcription, early
in a TAF independent manner to recruit TFIIB, and then again in a TAF
dependent manner, to recruit the other general transcription factors (Choy and
Green, 1993). However, recruitment of TFIIB does not result in activation in the
absence of TAFs. Nevertheless, one important step may be activator mediated
binding of TFIIB to TBP. An activation specific TBP mutant is defective in TFIIB
binding and does not allow VP16 mediated TFIIB recruitment into promoter
complexes (Kim, et al., 1994a). Thus, because activation has not been
observed in absence of TAFs, direct interactions between activation domains
and basal factors are not sufficient for activation. However, one important step
in activation may be the binding of TFIIB to TBP, which can be mediated by
direct interactions (Lin, 1991)(Lin, 1991; Kim, et al., 1994a).
Discovery of coactivators and their Isolation by biochemical means
Several lines of evidence suggest the existence of factors necessary for
activated but not basal transcription called transcriptional adaptors or
coactivators. First, recombinant TBP can only support basal but not activated
transcription whereas the TFIID fraction can support activated transcription as
well. It was therefore reasoned that TFIID must contain other proteins
necessary for activated but not basal transcription termed coactivators (Pugh
and Tjian, 1990).
Another line of evidence derives from studies of squelching in vitro by
GAL4-VP16. (Berger, et al., 1990). GAL4-VP16 can inhibit transcription from a
heterologous promoter in two different ways. Both basal and activated
transcription are inhibited by GAL4-VP16 when it is free to bind non-specific
sites on the DNA template. This "cis inhibition" results from trapping of basal
factors by GAL4-VP16, preventing transcription. Interestingly, only activated
transcription is inhibited when GAL4-VP16 is prevented from binding to the
template by a GAL4 oligonucleotide. This "trans-inhibition" suggests that GAL4-
VP16 is titrating a factor necessary for activated but not basal transcription,
which must be distinct from the basal factors. If a long oligo is used with a GAL4
site and a TATA box, both activated and basal transcription are inhibited,
arguing that cis inhibition is indeed due to basal factor sequestration (Wang, et
al., 1995). They called the factor necessary for activated but not basal
transcription an adaptor because mechanistically, it may be needed to bridge
the interaction between activation domains and basal factors.
Finally, a putative coactivator called the mediator was purified from yeast
that had the ability to overcome the squelching of basal and activated
transcription by GAL4-VP16 (Kelleher, et al., 1990). However, the composition
of the mediator was uncharacterized, and it was unclear whether the mediator
contained basal factors or other factors specific for activated transcription
(Kelleher, et al., 1990).
Since the existence of coactivators was discovered, many different
proteins have been proposed to be coactivators. In the following sections,
some of these coactivators will be discussed. Particular attention will be paid to
whether these molecules have demonstrated a stimulatory activity in vivo or in
vitro, what activators regulate this stimulatory activity, and what basal factors
respond to this activity. Some coactivators are previously isolated yeast
mutants with transcription defects. I will begin with coactivators for the
chromatin pathway, and then discuss coactivators that target basal factors.
Many of these coactivators operate by different mechanisms, which
demonstrates the complexity of transcription in eukaryotes.
Chromatin associated HMG proteins can function as coactivators in
vitro
HMG2 and HMG17 are both components of chromatin, and both can act
as coactivators (Paranjape, et al., 1995; Shykind, et al., 1995). HMG2 was
isolated by conventional chromatography as a coactivator activity that
stimulated GAL4-VP16 activation in the presence of TAFs (Shykind, et al.,
1995). Unlike the TAFs and other coactivators that will be discussed in the
following sections, a direct interaction between HMG2 and activation domains
or basal factors cannot be detected (Shykind, et al., 1995). Its strong stimulatory
activity is mediated through the TFIIA-TFIID complex, which may adopt a more
active conformation in the presence of HMG2 (Shykind, et al., 1995). The ability
of HMG2a to act as a coactivator on chromatin templates, a more physiological
context, has not been reported.
HMG1 7, on the other hand, acts as a coactivator to stimulate activated
but not basal transcription on chromatin templates (Paranjape, et al., 1995). On
naked DNA in the presence of basal factors and TBP, HMG17 mildly inhibits
transcription thus showing chromatin specifity. The mechanism of how HMG17
acts as a coactivator is unknown, but may function by allowing the basal
machinery to transcribe more effectively on a chromatin template (Paranjape, et
al., 1995). However, it was not reported whether HMG17 can stimulate
transcription in the presence of TAFs. In fact, the stimulatory activity of HMG2
and HMG17 have never been compared in the same assay. Thus, they may
operate by the same mechanism. Whether or not they do, chromatin factors can
clearly act as coactivators to stimulate transcription in vitro.
The SWIll, SWI2/SNF2, SWI3, SNF5 and SNF6 proteins are part of
a multi-subunit anti-histone complex
The SWI1, SWI2 and SWI3 genes and the SNF2, SNF5 and SNF6
genes were originally isolated in separate genetic selections for regulators of
HO endonuclease transcription and regulators of SUC2 expression respectively
(Neigeborn and Carlson, 1984; Stern, et al., 1984). SWI2 and SNF2 are the
same gene, and mutants in any of these SWI/SNF genes have similar
pleiotropic phenotypes (Peterson and Herskowitz, 1992). Importantly, all of
these genes are necessary for expression of several genes including HO,
SUC2, INO1, and GAL1-10 (Peterson and Herskowitz, 1992). In addition, the
snf and swi mutants can all be suppressed by mutations in SPT6 or SPT1 1,
strong genetic evidence that the SWI and SNF proteins have related functions
(Winston and Carlson, 1992).
The SWI11,2,3 and SNF5,6 proteins have been purified as members of a
large multi-subunit complex (Cairns, et al., 1994; Peterson, et al., 1994). This
complex contains at least 4 additional polypeptides by silver staining (Cairns, et
al., 1994). Recently a novel gene, SNF11, was identified by a two-hybrid
interaction with SNF2/SWI2, and shown to be an additional member of this
complex that can only be visualized by Coomassie blue staining (Treich, et al.,
1995).
Genetic and biochemical evidence suggests that the SNF/SWI complex
acts to antagonize histone repression. Mutations in genes encoding histone or
non-histone chromatin proteins such as H2A, H2B and SPT6, can suppress swi
or snf mutations suggesting that the SWI/SNF genes affect chromatin structure
(Winston and Carlson, 1992). Moreover, snf2 and snf5 mutants change the
micrococcal nuclease digestion patterns at the SUC2 promoter, perhaps
indicating a change from an open to a closed nucleosome structure. In (h2al-
h2bl),d snf5 double mutants, SUC2 expression, as well as an open
nucleosomal cleavage pattern are restored (Hirschhorn, et al., 1992). In vitro,
the SWI/SNF complex has the ability to allow GAL4-DNA binding domain
derivatives to bind to nucleosomal DNA (Cote, et al., 1994). The human
SWI/SNF complex also increases the binding of GAL4 as well as basal factors
to nucleosomal DNA (Imbalzano, et al., 1994; Kwon, et al., 1994).
20
In addition, the SWI/SNF complex may be recruited to promoters by
specific activators. A reporter regulated by GAL4 sites alone is SWI dependent,
suggesting the SWI genes are regulating the activity of GAL4 and not some
other element of the GALl-10 promoter (Peterson and Herskowitz, 1992).
Moreover, one SWI dependent activator, the glucocorticoid receptor
immunoprecipitates with SWI3 (Yoshinaga, et al., 1992). This interaction
depends on SWI1 and SW12 (Yoshinaga, et al., 1992), which argues that GR
may be physically associated with the entire SWI/SNF complex.
The need for an activator can be bypassed if a member of the SWI/SNF
complex is tethered to DNA by the lexA DNA binding domain. For example,
lexA-SNF2 activates transcription. Mutants in SNFS, SNF6 or SW11 reduce the
activity of lexA-SNF2 fusions, suggesting that an intact complex is necessary for
activation by lexA SNF fusions. This may indicate that the SWI/SNF complex
activates when recruited to DNA by SWI/SNF dependent activators. It is
currently not known why SWI/SNF dependent activators like GAL4 require the
SWI/SNF complex in order to alleviate chromatin repression, and how other
SWI/SNF independent activators deal with chromatin.
Two classes of SPT genes regulate transcription in chromatin and
non-chromatin pathways
Insertion of a Ty or a element (the Ty LTR) into a yeast promoter inhibits
or alters transcription of adjacent genes. Mutations in the SPTgenes were
isolated as suppressors of certain Ty or a insertions. For example, in the his4-
912o insertion, the a element TATA box is used preferentially over the HIS4
TATA box, in wildtype (SPT+) strains to produce a longer non-functional RNA
transcript. The longer transcript contains upstream ATG initiation codons which
initiate translation out of frame with the HIS4 coding sequence (revieved in
Winston, 1992).
spt mutants were classified according to which Ty or a insertions are
suppressed, as well as other common phenotypes. One group will be referred
to as the chromatin class because it includes SPT1 1 and SPT12 that encode
one of the two copies of the histone H2A and H2B genes (Clark-Adams and
Winston, 1988). The chromatin class also includes the SPT4, SPT5, SPT6
genes There is physical evidence that SPT5 and SPT6 physically interact, and
strong genetic evidence that SPT4, SPT5 and SPT6 are part of the same
complex (Swanson and Winston, 1992).
The chromatin class of SPT genes regulates Ty transcription, and act to
negatively regulate the transcription of several genes. Chromatin class spt
mutants can suppress snf2 mutants to restore expression of the SUC2 gene
(Hirschhorn, et al., 1992), and can suppress adrl mutants to allow ADH2
expression (Denis and Malvar, 1990). The putative SPT4, 5, 6 complex may be
acting to establish or maintain chromatin repression (Swanson and Winston,
1992). In fact, based on the ability of spt mutants to suppress snf/snf mutants,
the SNF/SWI complex may be negatively regulating the SPT4, 5, 6 complex that
in turn negatively regulates transcription via chromatin.
The other major class of SPT genes includes SPT15, which encodes the
yeast TBP gene (Eisenmann, et al., 1989; Hahn, et al., 1989). The SPT15/TBP
class also includes SPT3, SPT7 and SPT8 which share a number of pleiotropic
phenotypes, including slow growth, mating defects, and sporulation defects
(Eisenmann, et al., 1989). In addition, transcription of Ty elements, and other
yeast genes such as MFA1 is reduced (Hirschman and Winston, 1988). For Ty
or a insertions at the HIS4 locus, the decrease in the Ty transcript correlates
with a shift from the a TATA box to the normal HIS4 TATA box, allowing
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expression of the normal HIS4 transcript. However, a decrease in Ty
transcription is not sufficient to give an spt phenotype, because Ty transcription
is also lower in snf2 mutants, which do not have an SPT phenotype (Happel, et
al., 1991).
Because TBP binds to the TATA box, mutations in sptl5could change its
binding specificity and thus promoter selection in vivo. Indeed, seven of the
eight original sptl5 alleles have the same amino acid substitution in the TBP
coding sequence, which changes its DNA binding specificity in vitro (Arndt, et
al., 1992). This change appears to favor the natural HIS4 TATA box over the
TATA within the a element in vivo. Interestingly, the other allele spt15-21 has
the same DNA binding properties as wt TBP in vitro, and yet still shows a
change in promoter preference in vivo (Eisenmann, et al., 1992). The mutation
in sptl5-21 may be destroying an interaction with auxiliary factors that influence
promoter selection (Eisenmann, et al., 1994).
Mutations in spt3, spt7and spt8 show the same promoter preference
alteration as the sptl5 mutants (Winston, 1992). Allele specific suppression
and co-immunoprecipitation provides evidence for an interaction between
SPT3 and SPT15 (Eisenmann, et al., 1992). Further, some spt3 alleles that
suppress sptl5 also suppress an spt8 deletion, suggesting that SPT8 functions
to modulate the SPT3-TBP interaction (Eisenmann, et al., 1994). Although
SPT7 has not been directly linked to the other members of this group by genetic
or physical means, the phenotypes of spt7 mutants are the same as the other
members of this group, suggesting it may be in the same complex (Gansheroff,
et al., 1995). Thus, SPT3, SPT7 and SPT8 may be acting as coactivators in a
complex with TBP to regulate promoter selection (Winston, 1992).
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The TBP-associated factors (TAFs) are coactivators tightly
associated with TBP
The TAFs are one of the earliest identified and best characterized
examples of coactivators. They co-purify with TBP in Drosophila and Hela
extracts, and are necessary for activated but not basal transcription (Dynlacht,
et al., 1991). Several of the TAFs show striking conservation from Drosophila to
humans in terms of sequence similarity and biochemical activity (Thut, et al.,
1995). TAFs have also been identified in yeast (Poon and Weil, 1993; Reese, et
al., 1994).
Studies of individual TAFs and specific TAF subcomplexes reconstituted
from recombinant TAFs suggest several general principles for TAF mediated
activation. First, there is specificity in TAF-activation domain interactions. For
example, TAF110 interacts specifically with the Glutamine rich activation
domain of SP1, whereas TAF 40 and TAF60 interact with VP16 and p53, acidic
activation domains (Goodrich, et al., 1993; Hoey, et al., 1993; Thut, et al., 1995).
Second, for a TAF subcomplex to respond to an activator, it must have a TAF
subunit that can bind to its activation domain. For example, a TAF60, TAF250
and TBP subcomplex can mediate activation by VP16 or p53 but not SP1.
Alternatively, a subcomplex with TAF110, TAF250 and TBP can mediate
activation by SP1 but not VP16. As expected, subcomplexes with both TAF110
and TAF60 can mediate activation by either activator (Chen, et al., 1994). Third,
a TAF that binds an activator must itself interact with a TAF or TAFs binding TBP
in order to mediate activation. An activation domain-TAF interaction alone is not
sufficient for activated transcription. For example, TAF110 is sufficient to
promote activated transcription by SP1 when it is tethered to TBP by either
TAF250 or TAF30a (Yokomori, et al., 1993). Hence, the TAF complex acts as a
transcriptional adaptor, that mediates activation by specific protein-protein
interactions with activation domains and basal factors.
In addition, different TAF complexes with distinct activities have been
isolated from human cells (Brou, et al., 1993). TAF30 was cloned as a member
of one particular complex (Jacq, et al., 1994). This TAF, and its specific TAF
complex, is necessary for activation by an Estrogen Receptor (ER) activation
domain, but not by the VP16 activation domain, which itself activates through
other TAFs and a different TAF complex (Jacq, et al., 1994). This work is
particularly important because it supports the aforementioned model that a TAF
complex will support activation only if a component of the complex can bind to
the activator. Furthermore, it suggests that the composition of TAF complexes
may vary from cell to cell or from promoter to promoter, and determine which
activation domains a promoter can respond to. In fact, TAF150 and TFIIA may
help govern the developmental switch from the proximal to the distal ADH
promoter in Drosophila (Hansen and Tjian, 1995).
Multiple TAF complexes have also been isolated in yeast (Poon and
Weil, 1993; Reese, et al., 1994). Immunoprecipitation of TBP from yeast extracts
simultaneously isolates at least three TAF complexes, including a specific Pol III
complex, a putative repression complex containing MOT1,1 and a Pol II
complex (Poon, et al., 1994). Thus far, none of the SPT15-associated SPT
genes have been identified as a TAFs. One member of the Pol II complex is
TSM-1, the yeast homolog of the Drosophila TAF150 gene(Poon, et al., 1994)
(Verrijzer, et al., 1994). The Pol II TAFs were also isolated by purification of an
activity retained on a GST-TBP column necessary for activated but not basal
1 MOT1 is an ATP dependent negative regulator of TBP binding in vitro, and acts as a negative
regulator of basal transcription in vivo (Auble, et al., 1994; Davis, et al., 1992).
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transcription in vitro (Reese, et al., 1994). Two of these genes were cloned and
show sequence homology to Drosophila TAFs (Reese, et al., 1994).
Several experiments have also addressed the role of TAFs in vivo.
TAF250 is identical to CCG1, originally cloned by complementation of a
recessive temperature sensitive mutation in a cell line (Hisatake, et al., 1993;
Ruppert, et al., 1993; Sekiguchi, et al., 1988). This taf250 allele results in
activator specific activation defects and cell cycle arrest at the non-permissive
temperature showing that TAF250 mediates activation in vivo (Wang and Tjian,
1994) In another study, mutants in TBP with reduced affinity for TAF250 in vitro
show reduced ability to support activation in vivo, suggesting that TAF250 helps
mediate activation in vivo by interacting with TBP (Tansey, et al., 1994). Finally,
the yeast TAFs TSM- 1, yTAF145 and yTAF90 are essential for viability (Reese,
et al., 1994; Verrijzer, et al., 1994).
CBP and p300 are members of a family of coactivators targeted by
E1A during tumorogenesis.
Unlike TAFs, which were identified as coactivators by association with
the basal factor TBP, CBP was identified by its ability to bind specifically to the
transcriptionally active (i. e. phosphorylated) form of CREB, a transcriptional
activator (Chrivia, 1993). Transfection experiments show that CBP can
potentiate CREB activation in vivo, and that CBP itself can trans-activate when
tethered to DNA (Chrivia, 1993; Kwok, et al., 1994). Furthermore, CBP binds
the basal factor TFIIB (Kwok, et al., 1994). This suggests that like the TAFs, CBP
functions as an adaptor molecule, in this case mediating the interaction
between CREB and TFIIB.
CBP is a member of a family of related proteins, including the E1A-
associated protein p300 (Lundblad, et al., 1995). p300 had previously been
26
proposed to be a coactivator for the SV40 enhancer locus that is inactivated in
vivo by E1A binding (Eckner, et al., 1994). In fact, p300 is indistinguishable
from CBP for CREB binding and CREB mediated activation. Moreover, E1A
also binds to CBP (Lundblad, et al., 1995). Interestingly, part of the tumorogenic
activity of E1A derives from its ability to bind and inactivate the p300/CBP
adaptors, thereby repressing transcription (Eckner, et al., 1994; Lundblad, et al.,
1995).
Promiscuous adaptors respond to a variety of activation domains
The TAFs and p300/CBP are transcriptional adaptors that mediate
activation via interactions between one type of activation domain and one
particular adaptor. There are other types of coactivators that function as
promiscuous adaptors that can bind and respond to different types of activators.
For example, TAF55 binds to the diverse transcriptional activators Spl, YY1,
USF and CTF (Chiang and Roeder, 1995). Furthermore, TAF55 interacts with
the DNA binding domain of SP1 (Chiang and Roeder, 1995), unlike TAF110
which responds to SPi's glutamine rich activation domain (Hoey, et al., 1993).
This suggests that TAF55 may act by a different and perhaps more general
mechanism (Chiang and Roeder, 1995). Unlike many other TAFs, however, the
role of TAF55 in transcription is only inferred by its association with a human
TAF complex and its ability to bind activators. Further characterization,
including in vitro transcription and mutant analysis is needed to confirm and
elucidate its role in transcription.
PC4/p15 is a more thoroughly characterized promiscuous adaptor. PC4
binds directly to acidic activation domains (Ge and Roeder, 1994) as well as to
a TBP TFIIA complex (Ge and Roeder, 1994; Kretzschmar, et al., 1994). The
importance of these interactions are confirmed in two ways. First, recombinant
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PC4/p15 can stimulate activation from a variety of activation domains in a
manner dependent on TAFs (Ge and Roeder, 1994; Kretzschmar, et al., 1994).
Further, depletion of p15 from crude transcription systems lowers activated but
not basal transcription (Kretzschmar, et al., 1994). The TAF dependent
PC4/pl 5 activation may be analagous to the TAF dependent activation
associated with VP16 mediated TFIIB recruitment into initiation complexes
(Choy and Green, 1993). PC4/pl5 can which can interact with basal factors
and activation domains is not sufficient for activation, just as direct interactions
between TFIIB and activation domains are not sufficient for activation. CBP,
which binds the activator CREB and TFIIB, may also require the TAFs for
activation in vivo.
Genetic isolation of the SRB genes led to the identification of the
RNA Polymerase II Holoenzyme
Suppression analysis uses the awesome power of yeast genetics to
isolate novel factors (G. Fink, personal philosophy). Nine SRB genes were
isolated as dominant and recessive allele specific suppressors of a conditional
truncation mutant of the CTD of RPB1 (Hengartner, et al., 1995, and references
therein). The SRB proteins play an important if not essential role in transcription
of mRNA in vivo and in vitro. All nine SRBs co-fractionate in a large multi-
subunit complex called the RNA Polymerase II holoenzyme (Hengartner, et al.,
1995; Koleske and Young, 1994). In addition to the SRBs, this complex
contains RNA Polymerase II, TFIIB, TFIIF, TFIIH as well as a number of
unidentified polypeptides(Koleske and Young, 1994). A closely related
holoenzyme was purified that did not contain TFIIB and TFIIH (Kim, et al.,
1994b). With the addition of the missing basal factors, the holoenzyme is
capable of both basal and activated transcription (Kim, et al., 1994b; Koleske
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and Young, 1994). Importantly, core polymerase (i.e. the 11 subunit complex
isolated by affinity purification) in reconstituted transcription systems using TBP
and basal factors is not able to respond to transcriptional activators.
The SRBs can also be isolated as part of a complex independent of Pol II
called the mediator. The mediator stimulates basal transcription and allows
activated transcription when added to a reconstituted in vitro transcription
system (Hengartner, et al., 1995; Kim, et al., 1994b). Because addition of the
mediator is sufficient to allow activation, it can be considered a transcriptional
coactivator. In addition, both the mediator and holoenzyme are capable of
binding to the VP16 activation domain (Hengartner, et al., 1995). Because the
mediator is sufficient to allow activated transcription, and can bind activation
domains and basal factors, it has the properties of a transcriptional adaptor
complex.
Characterization of individual SRBs demonstrates the diverse functions
of the holoenzyme. For example, dominant mutations in SRB2 and SRB5 were
isolated as suppressors of conditional CTD truncations (Nonet and Young,
1989; Thompson, et al., 1993). Deletion mutants of either of these genes,
however, display a phenotype similar to CTD truncation mutants, and are
inviable when the CTD contains less than 20 repeats (Koleske, et al., 1992;
Thompson, et al., 1993). In vitro, SRB2 and SRB5 associate with pre-initiation
complexes, and are necessary for basal and perhaps activated transcription
(Koleske, et al., 1992; Thompson, et al., 1993). In addition, SRB2 interacts with
TBP (Koleske, et al., 1992).
The SRB10 and SRB11 genes, isolated as recessive suppressors of
conditional CTD truncations, encode kinase and cyclin like proteins and
function together as a kinase/cyclin pair (Liao, et al., 1995). srb10 deletion
mutant strains are defective in GAL induction, thus displaying a transcription
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defect in vivo (Liao, et al., 1995). In vitro, holoenzyme lacking SRB10 show
normal activated and basal transcription (Liao, et al., 1995). However, the CTD
is underphosphorilated, suggesting that SRB10 has CTD kinase activity (Liao,
et al., 1995). This is in agreement by work by others who have shown that CTD
phosphorilation is unnecessary for transcription in vitro (Malaka, et al., 1995).
Presumably, the factors that respond to SRB10 regulation in vivo are not
present or active in this in vitro system (Liao, et al., 1995).
Finally, the SRB4, SRB6 and SRB7 genes are essential for viability
(Thompson, et al., 1993). Interestingly, inactivation of SRB4 using a
temperature sensitive allele results in a shutdown of all mRNA synthesis in the
cell (Thompson and Young, 1995). This argues that SRB4 and perhaps the
holoenzyme is essential for all mRNA transcription in vivo (Thompson and
Young, 1995).
GAL11 and SUG1, putative coactivators in the holoenzyme
GAL1 1 was first identified as a factor needed for full expression of
Galactose inducible genes (Nogi and Fukasawa, 1980). In fact, GAL4 levels
are unaffected while GAL4 activity is reduced five fold in gall 1 mutants (Suzuki,
et al., 1988). Additionally, gall1 mutants were isolated in selections for Ty
suppressors and SUC2 regulators, suggesting that GAL1 1 also regulates GAL4
independent activity. Indeed, gall 1 mutants have pleiotrophic phenotypes,
some of which correlate with reduced gene expression (Fassler and Winston,
1989; Nishizawa, et al., 1990). For example, gall11 mutants mate poorly, and
show reduced expression of the MATa locus (Fassler and Winston, 1989). In
certain contexts, including Ty suppression, GAL1 1 acts as a negative regulator.
Thus, genetic analysis reveals that GAL1 1 is both a positive and negative
regulator of gene expression in vivo (Fassler and Winston, 1989).
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A particular allele of GAL1 1, called GAL 11P (for Potentiator) was isolated
as a dominant mutation that has the ability to make certain weak activators with
GAL4 DNA binding domains behave as strong activators (Himmelfarb, et al.,
1990). GAL 11P and gall1 phenotypes argue that GAL11 binds GAL4, and acts
as a cofactor in trans-activation (Himmelfarb, et al., 1990). The detection of
GAL1 1 in the holoenzyme is consistent with this model (Kim, et al., 1994b).
In fact, the GAL1 1P mutation creates a novel contact between an inert
portion of the GAL1 1 protein and the dimerization region of GAL4 (Barberis, et
al., 1995). This suggests that contact between a DNA binding protein and a
component of the holoenzyme is sufficient for activation, a mechanism that may
be used by bonafide activators in vivo. This does not, however, explain the
normal function of GAL 11 to promote transcription as a member of the
holoenzyme. It may itself be a target of activation domains, acting as an adaptor
associated with basal factors. On the other hand, it may act to stabilize the
holoenzyme without interactions outside of the complex.
SUG1 is a putative coactivator that superficially shares some
characteristics with GAL1 1. Like the GALl 1P allele, mutations in SUG1 were
isolated in a selection for suppressors of a weak activator, in this case a GAL4
derivative missing its activation domain (Swaffield, et al., 1992). This recessive
mutant allele increases the activity of the GAL4 variant by at least ten fold, but
does not alter the activity of wildtype GAL4 (Swaffield, et al., 1992). Thus, it was
argued that SUG1 acts as a transcriptional coactivator. Moreover, like GAL1 1,
SUG1 was found to be a part of the holoenzyme (Kim, et al., 1994b).
However, SUG1 was also identified as a member of the 26S protease,
which cast some doubt on its role as a coactivator, but would not necessarily
rule out a function in transcription (Ghislain, et al., 1993). This contention was
refuted by a low resolution experiment showing that epitope tagged SUG1 did
not co-sediment with the proteosome but rather with the holoenzyme (Swaffield,
et al., 1995). However, in recent analysis of the Young lab holoenzyme, SUG1
could not be detected. Given the sensitivity of the a-SUG1 antibodies, if SUG1
is present in the holoenzyme, there are only trace amounts (1% or less)
compared to the level of the SRB proteins, (Rick Young, personal
communication). Thus, at present, the role of SUG1 in transcription is unclear.
Isolation of ADA genes in a selection for transcriptional adaptors
Mutations in five genes, ADA1, ADA2, ADA3, GCN5 and ADA5 were
isolated in a selection for mutations resistant to toxicity mediated by
overexpression of a powerful transcriptional activator, GAL4-VP16 (Berger, et
al., 1992; Marcus, et al., 1994). It was hypothesized that toxicity is caused by
the trapping of basal factors at nonspecific sites on genomic DNA. Mutations in
adaptor molecules that mediate the interaction between the activation domain
and basal factors would free the basal factors to allow transcription (Berger, et
al., 1992). The ADA genes are necessary for activation by certain activation
domains in vivo and in vitro (Berger, et al., 1992; Marcus, et al., 1994; Pifa, et
al., 1993). Characterization of the ADA genes will be the subject of this thesis.
Isolation and initial characterization of ada2 and ada3 mutants has been
described elsewhere. ada2 and ada3 deletion mutants have similar
phenotypes including slow growth on minimal medium, and temperature
sensitivity (Berger, et al., 1992; Pifia, et al., 1993). Furthermore, they are
defective in activation mediated by the VP16 and GCN4 but not the HAP4 and
GAL4 activation domains in vivo (Berger, et al., 1992; Pifa, et al., 1993). In
addition, nuclear extracts from ada2 mutants have normal basal transcription
and can support activated transcription from the HAP4 activation domain.
GAL4-VP16 or GCN4, on the other hand, poorly activate in ada2 extracts
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(Berger, et al., 1992). Thus, activation domains have the same ADA2 specifity
in vivo and in vitro.
ada2ada3 double deletion mutants have the same slow growth
phenotype as the single deletion mutants, suggesting that ADA2 and ADA3 act
in the same pathway or as a complex in vivo (Piha, et al., 1993). In fact, in vitro
translated ADA2 and ADA3 coimmunoprecipitate (Horiuchi, et al., 1995)., and
ADA2 and ADA3 copurify through four chromotography steps from yeast
extracts (N. Silverman and LG, unpublished data).
In Chapter 2 and Chapter 3, I will discuss the isolation of GCN5 in the
toxicity screen, and its characterization. Biochemical and genetic evidence
argues that GCN5 functions in a complex with ADA2 and ADA3 in vivo. In
addition, I show that the bromodomain, conserved in many different
coactivators, is necessary for full activity by GCN5-dependent activators. In
Chapter 4, I report the cloning and characterization of ADA5. ADA5 mutants
have different characteristics than ada2, ada3 and gcn5 mutants. Moreover,
ADA5 is not part of the ADA2 complex. Therefore, ADA5 is a novel class of ADA
gene. Chapter 5 will discuss the ADA genes in the context of the coactivator
field.
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Chapter 2
Functional Similarity and Physical Association Between GCN5 and
ADA2: Putative Transcriptional Adaptors.
This chapter is adapted from Marcus, G.A., Silverman, N., Berger, S.L.,
Horiuchi, J. and Guarente, L. (1994). Functional similarity and physical
association between GCN5 and ADA2: Putative transcriptional adaptors. EMBO
J 13, 4807-4815.
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INTRODUCTION
Transcriptional activation in eukaryotes involves the functional interaction
between transcriptional activators bound at enhancers or UASs and the general
transcription factors bound at the TATA box. Activators are modular, containing
DNA binding domains and activation domains (Hope and Struhl, 1986). One
class of activation domains is enriched in amino acids with acidic side chains
and can function in a wide variety of eukaryotes ranging from yeast to mammals
(Sadowski, et al., 1988). Acidic activators function when bound at sites very
distant from the TATA box. Models for activation include direct protein-protein
contact between activation domains and general factors (Lin, 1991; Lin, et al.,
1991) (looping out intervening DNA) and disruption of chromatin, which results
in an alleviation of repression (Croston and Kadonaga, 1993; Han, 1989;
Workman, 1992).
Whatever their mechanism of action, activators require novel protein
factors to potentiate their full activity. One class of these factors termed
coactivators are tightly associated with the TATA binding protein (TBP) and
comprise a TFIID complex (Dynlacht, et al., 1991). These TBP-associated
proteins (TAFs) evidently serve as sites in the general machinery to which
activators can bind (Goodrich, et al., 1993; Hoey, et al., 1993). Another class
are products of yeast genes SW11-3 and SNF5,.6 which comprise a single
complex (Peterson, et al., 1994) (Cairns, et al., 1994). These proteins may
function through chromatin because suppressers that bypass the requirement
for them lie in histone (Hirschhorn, et al., 1992) and non-histone chromatin
proteins (Winston and Carlson, 1992). In addition, the SWI/SNF complex
promotes the binding of GAL4 derivatives to nucleosomal DNA in an ATP
dependent manner (Verrijzer, et al., 1994).
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A third class of cofactors required for activation includes products of the
yeast ADA2 and ADA3 genes. Mutations in these genes were selected since
they confer resistance to the toxic chimeric activator GAL4-VP16, containing the
DNA-binding domain of GAL4 and the acidic activation domain of VP16
(Berger, et al., 1992). The toxicity of the chimera correlates with its unusual
potency as an activator because mutations in VP16 which reduce activation
also reduce toxicity (Berger, et al., 1992). Mutations in ADA2 and ADA3 allow
cells to tolerate the chimera, and also reduce their ability to respond to certain
transcriptional activators, including VP16 and GCN4 (Berger, et al., 1992; Pifia,
et al., 1993).
We have argued that ADA2 and ADA3 could be adaptors that bridge
interactions between activation domains and general factors at promoters. This
conclusion comes from two observations. First, the VP16 activation domain can
be made to bind and sequester factor(s) needed for transcriptional activation
but not for basal transcription in vitro, demonstrating that adaptors exist (Berger,
et al., 1990). Second, mutations in ADA2or ADA3 reduce activation by some,
but not all, acidic activation domains in vivo and in vitro (Berger, et al., 1992;
Piia, et al., 1993). This specificity argues for a functional interaction between
the ADAs and specific activation domains.
Another yeast gene product that has been implicated in transcription is
GCN5. Mutations in GCN genes cannot derepress HIS3 and other genes that
respond to the general amino acid control system (Hinnebusch and Fink, 1983;
Penn, et al., 1983). This failure to derepress results from a defect in the
synthesis, stability, or activity of the activator, GCN4. Whereas mutations in
GCN1-3 exert their effects by lowering translation of GCN4 mRNA (Hinnebusch,
1985), mutations in GCN5do not affect the level of GCN4 protein, but rather
reduce its ability to activate transcription (Georgakopoulos and Thireos, 1992).
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Thus, it has been proposed that GCN5 could be a coactivator that augments the
activity of GCN4 (Georgakopoulos and Thireos, 1992).
The GCN5 sequence has a domain at the carboxyl terminus, the
bromodomain, that is highly conserved in other proteins involved in
transcription, including brahma from Drosophila (Tamkun, et al., 1992), yeast
SW12 (SNF2) (Laurent, et al., 1991), yeast SPT7 (Haynes, et al., 1992), the
EIA-associated protein p300 (Eckner, et al., 1994), and mammalian TAF250
(CCG1) (Ruppert, et al., 1993). The conservation is very high as illustrated by
the 50% identity between GCN5 and CCG1 across the 70 amino acid
bromodomain. The presence of the bromodomain in this apparently diverse set
of transcription factors suggests that it is an important functional domain.
However, attempts to show functionality of the bromodomain in these proteins
have not yet succeeded (Elfring, et al., 1994; Laurent, et al., 1993).
Previously, we isolated ten alleles of ADA 1, but only two alleles of ADA2
and one allele of ADA3. Here, we demonstrate use of the same selection on a
much larger scale to identify more genes. In addition to isolating more alleles of
ADA 1, ADA2 and ADA3, we identify two new genes with similar properties. We
show that one of these genes is GCN5, and demonstrate a physical interaction
between GCN5 and ADA2 in vivo and in vitro. This provides the first direct
indication that the GAL4-VP16 resistant mutants might define a set of proteins
that comprise a single multi-protein complex involved in transcriptional
activation. Finally, we show that the bromodomain is important in the function of
GCN5.
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RESULTS
Selection of GAL4-VP16-resistant mutants
The yeast strain BP1, which was used in the selections that yielded ada2
and ada3 mutants, (Berger, et al., 1992) was mutagenized and transformed with
a high copy plasmid expressing GAL4-VP16 from the constitutive ADH1
promoter. 300 colonies showing resistance to GAL4-VP16 were analyzed as
summarized in Table 1. In order to identify recessive chromosomal mutations,
the candidates were mated to a wild type strain. 50 of the resulting diploid
strains displayed sensitivity to GAL4-VP16, indicating that the mutation
conferring resistance in the haploid was recessive. In the remaining 250
candidates the plasmid was removed and the resulting strains were mated to an
ada2 mutant bearing GAL4-VP16. All 250 diploids were sensitive to GAL4-
VP16, indicating that resistance of the haploid mutants was due to a mutation
on the original GAL4-VP16 expression plasmid. Thus, in none of the 300
strains was resistance due to a dominant chromosomal mutation.
The recessive mutants were characterized further by mating to adal,
ada2, or ada3 tester strains. Candidates that failed to complement an ada
mutation would give rise to diploids that were resistant to GAL4-VP16. Slow
growth of the diploid would provide a further indication of a failure to
complement. By these tests, we identified five new alleles of ADA1, eight new
alleles of ADA2, and 12 new alleles of ADA3. Among the remaining mutants,
complementation tests indicated two new groups termed ADA4 (three mutants)
and ADA5 (one mutant). Complementation tests in other mutants were
incomplete, and further analysis is needed to group them.
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TABLE .1Selection for mutants resistant to GAL4-VP16 results in
additional alleles of ADA1, ADA2, and ADA3, as well as alleles of
two new genes.
PRIMARY TRANSFORMANTS: 300,000
PLASMID MUTANTS 250
ADA1 ALLELES 5
ADA2 ALLELES 8
ADA3 ALLELES 12
ADA4 ALLELES 3
ADA5 ALLELES 1
LEGEND. BP1 was mutagenized and transformed with pGAL4-VP16 Ura as
described in Methods. Approximately 300 large colonies showing resistance to
the toxic plasmid were picked. The majority of these appeared to be linked to
the plasmid expressing GAL4-VP16, as described in Methods. Other strains
were characterized as adal, ada2, or ada3 alleles by mating to a mutant tester
strain and scoring the growth of the diploid on minimal medium as well as its
resistance to GAL4-VP16 overexpression. Representative strains were
transformed with the appropriate clone for confirmation. From tetrads, we
obtained some of these resistant mutations in strains of the opposite mating
type. Crossing among mutants was used to identify the ADA4 and ADA5
complementation groups.
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Cloning of ADA4 and its identification as GCN5
We chose to focus on ADA4, in part, because mutants displayed
extremely slow growth on minimal media, a phenotype also seen in ada2 and
ada3 mutants. Tetrad analysis indicated that slow growth and resistance to
GAL4-VP16 co-segregated as a single mutation (not shown). ADA4 was cloned
on a 12 Kb fragment from a yeast genomic library by restoration of normal
growth to an ada4 mutant strain. This clone also restored sensitivity to GAL4-
VP16. The complementing fragment was subcloned to a 2.2 Kb fragment as
described in Methods. The sequence at one end of the subclone corresponded
to a portion of the PUP2 gene which is adjacent to GCN5 (Georgatsou, et al.,
1992). Therefore, we determined whether the gene complementing the ada4
mutation was indeed GCN5. Restriction analysis revealed that the entire GCN5
coding sequence lay within this 2.2 KB. Furthermore, a 1.8 Kb Xhol-Pstl
fragment containing the GCN5 sequence (Georgakopoulos and Thireos, 1992)
complemented the ada4 mutant. Lastly, the specific GCN5 coding sequence
amplified by PCR and placed under control of the ADH1 promoter also
complemented the mutant.
To confirm that the ada4 mutation was in GCN5, the 1.8 Kb Xhol-Pstl
fragment was cloned into an integrating vector bearing the URA3 marker and
targeted to the GCN5 locus. The strain containing the integrant was mated to
the ada4-1 mutant and the diploid sporulated. In 6/6 tetrads two segregants
grew well and were Ura+, and two grew slowly and were Ura-, thus showing
linkage between GCN5 and ADA4 (hereafter designated GCN5).
gcn5 mutants exhibit reduced activation by some activation
domains in vivo
The GCN5 gene was deleted as described in Methods. The resulting
strain shared several phenotypes with ada2 and ada3 deletion mutants,
including resistance to GAL4-VP16, slow growth on minimal media, and
temperature sensitivity (not shown) on minimal or rich media.
Trans-activation by GAL4-VP1 6 was tested in the gcn5 deletion mutant
by introducing a low copy plasmid expressing GAL4-VP16 or GAL4-VP16FA,
(with a Phe 442-Ala mutation) (Cress and Triezenberg, 1991). As shown in
Table 2, the ability of GAL4-VP16 to activate a reporter bearing lacZ under
control of the GAL1-10 UAS was reduced over 20-fold in the gcn5 mutant and
the activity of GAL4-VP16FA was reduced over 40-fold. The gcn5-1 mutant
strain showed a similar defect in the ability of GAL4-VP16 to activate
transcription (not shown). The levels of GAL4-VP16 FA protein in the wild type
and mutant strains were determined by gel shift analysis and were similar i. e.
protein levels in the mutant were reduced by less than two fold (not shown).
We next tested the acidic activation domains of GCN4, GAL4, and HAP4,
which were each fused to the lexAl-202 moiety and assayed using a lacZ
reporter under control of a single lexA site (Table 2). The activity of the GCN4
domain was reduced about four and a half fold in the gcn5 deletion, whereas
the activities of the GAL4 and HAP4 domains were only affected about two fold.
These activation domains had similar activities in the gcn5-1 mutant (not
shown). The levels of the lexA fusion proteins were comparable (less than two
fold difference) in the wild type and gcn5 - mutant by Western blot analysis
using anti-lexA antibody (not shown). This pattern of the activation domain
defects in the gcn5 strain recapitulated effects observed in ada2 and ada3
mutant strains (Piia, et al., 1993).
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TABLE 2 (Following page)
LEGEND. Trans-activation by GAL4-VP16 and lexA activation domain fusions in
a gcn5 mutant and ada2gcn5 double mutant. An ARS-CEN plasmid expressing
GAL4-VP16 or GAL4-VP16FA was transformed into a wild type, and a Agcn5
strain. The strains were also transformed with pLGSD5, a reporter plasmid with
lacZ under GAL4 control. The lexA activation domain fusions, on an ARS-CEN
plasmid, were transformed into those strains, as well as into an isogenic
ada2gcn5 double deletion strain, along with Yep21-Sc3423 (Hope and Struhl,
1986), which contains the lacZ gene under the control of a lexA operator site.
The specific activity of 8-galactosidase averaged form at least three
independent experiments (S.D. <20%) is presented. pLGSD5 gives a
background of 4-5 units, and Yep21-Sc3423 plus lexA202 alone gives 10-20
units of activity (not shown). Levels of GAL4-VP16 FA were determined in wild
type and gcn5-1 strains by gel shift of a GAL4 site and were similar (data not
shown). Likewise, levels of each lexA fusion protein were compared in extracts
from wild type and gcn5-1 cells by Western analysis using anti-lexA antibody
and were comparable (data not shown).
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TABLE 2. Trans-activation by GAL4-VP16 and lexA activation
domain fusions in a gcn5 mutant and ada2gcn5 double mutant.
WT
GAL4-VP16
GAL4-VP1 6
WT
FA
LEX-GAL4
LEX-GCN4
LEX-HAP4
17872
6406
4049
1785
4133
Agcn5
814
144
1823
404
2508
Agcn5
Aada2
ND
ND
1433
300
2303
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ada2 gcn5 and ada3 gcn5 double mutants
Since gcn5 null mutations displayed very similar properties to null
mutations in ADA2 and ADA3, we constructed double mutants between GCN5
and the ada mutants. If the genes operated in the same pathway, or as a
complex, the double deletion strain should not have a more severe phenotype
than either of the single mutants. gcn5 ada2 and gcn5 ada3 double deletion
mutants were generated in the BWG1-7A background as described in Methods.
The slow growth phenotype of these strains could be restored to wild type only if
they were transformed with both a plasmid bearing GCN5 and a plasmid
bearing the appropriate ADA gene. Importantly, these double mutants behaved
similarly to ada2 ada3 double mutants (Piia, et al., 1993), in that they grew no
more slowly than the single mutants did (data not shown). Furthermore, the
level of trans-activation by lexA-GCN4, lexA-HAP4, and lexA-GAL4 in an ada2
gcn5 double mutant is similar to that in a single deletion mutant in gcn5 (Table
2) or ada2 (not shown) This is strong genetic evidence that ADA2, ADA3 and
GCN5 function in the same pathway or as a complex in vivo.
lexA-ADA2 and lexA-ADA3 activate transcription in a GCN5-
dependent manner
ADA2 and ADA3 were tested for their ability to activate transcription
when fused to the lexA202 moiety. These fusions both complement a mutation
of the cognate ADA gene. Table 3 indicates that these fusions were
transcriptionally active and that their activities were greatly reduced in a gcn5
mutant strain. Further, the activity of lexA-ADA2 was reduced in a ada3 mutant,
and vice versa (unpublished data). These findings provide further evidence for
a functional interdependence between GCN5 and the ADA genes, but they
must be interpreted with caution (see Discussion).
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TABLE 3. lexA-ADA2 and lexA-ADA3 activate transcription in a
GCN5 dependent manner.
LEX-ADA2
LEX-ADA3
WT
179
173
Agcn5
63
42
LEGEND. The wild type and gcn5 deletion strains BP1 and GMy25 were
transformed with plexA-ADA2 or plexA-ADA3 and the lacZ reporter Yep21-
Sc3423 (Hope and Struhl, 1986). Levels of 8-galactosidase were measured as
in Table 2.
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GCN5 binds to ADA2 In vivo and in vitro
The above observations are consistent with the possibility that GCN5
binds to ADA2. To test whether ADA2 and GCN5 do indeed interact, we carried
out two-hybrid studies (Fields and Song, 1989) between lexA-GCN5 and ADA2
fused to a portion of the VP16 activation domain (residues 452-490 see
Methods). Both the GCN5 and ADA2 fusion proteins retain the ability to
complement the respective mutations in vivo and thus retain function. As shown
in Figure 1, the activity of lexA-GCN5 is stimulated about 50-fold by ADA2-VP16
as compared to overexpression of ADA2 alone. The lexA DNA binding domain
(1-202) alone was not affected at all by ADA2-VP16. This finding suggests that
GCN5 and ADA2 interact in vivo.
The two-hybrid experiment does not distinguish direct binding of GCN5
to ADA2 from an interaction that may be mediated by other proteins. In order to
determine whether GCN5 and ADA2 interact with each other directly, we
translated both proteins in a reticulocyte lysate programmed with mRNA from
the ADA2 and GCN5 genes. As a control we co-translated each gene with
luciferase. Precipitation was carried out with antibody to ADA2 (see Methods).
Figure 2 shows that GCN5 was clearly co-precipitated with ADA2. In the
absence of ADA2, the antibody did not precipitate any GCN5. Further,
luciferase was not co-precipitated when translated with ADA2. These results
suggest that there is a direct physical interaction between GCN5 and ADA2.
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FIGURE 1. GCN5 interacts with ADA2 by Two Hybrid Analysis. BWG1-7a was
transformed with a plasmid containing the lexA DNA binding and dimerization
domains fused to GCN5 or GCN5A bromo. A second plasmid expressed either
ADA2, ADA2VP16 or neither protein. The strain also contained the lacZ gene
under control of a single lexA operator in plasmid pRbHis (gift of John Fikes).
Specific activity of 3-galactosidase is shown which represents the mean of at
least three independent experiments with an error of less than 20%. In addition
the control of lexA 1-202 alone gave 25 units of activity, and varied by less than
two units when ADA2 or ADA2VP16 were coexpressed (data not shown).
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FIGURE 2 (Following page). The GCN5 protein co-precipitates with ADA2.
ADA2 was co-translated with GCN5, GCN5Abromo, or luciferase in reticulocyte
lysate incorporating 35S-Methionine. GCN5 and GCN5A were also co-
translated with luciferase as a control. Lanes 6-10 show the products of these
translations as the "input". '+' indicates which proteins were translated. These
lysates were precipitated with anti-ADA2 antibody and the pellets were boiled
and loaded on a 10%SDSPAGE gel as described in Methods. Lanes 1-5 show
the "precipitate".
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The GCN5 bromodomain is functional
In order to test whether the bromodomain is important in the function of
GCN5, we generated a version of GCN5 by PCR that deleted the bromodomain
(see Methods). The N-terminal primer was designed to fuse the influenza
hemagglutinin (HA) epitope at the amino terminus of the gene. As shown in
Figure 3, the HA epitope tag itself had no effect on the ability of GCN5 to
complement a mutant. However, GCN5 missing its bromodomain (GCN5A)
only weakly complemented a gcn5 deleted strain for growth on minimal plates.
We suspected the growth defect in a GCN5A strain was do to a defect in
transcription. Therefore, we assayed lexA-GCN4, lexA-HAP4 and lexA-GAL4
for their ability to trans-activate in a gcn5 deletion mutant complemented with
either full length GCN5, or GCN5A. The ADA dependent activation domain of
GCN4, showed a partial reducion in its ability to activate transcription in the
absence of the bromodomain, whereas the largely ADA independent GAL4
and HAP4 activation domains did not (Figure 4). Finally, to determine if GCN5A
can restore GAL4-VP16 toxicity, a gcn5 deletion strain was cotransformed with
GAL4-VP16 and either GCN5, or GCN5A. As shown in Figure 5,
cotransformation of GCN5 and GAL4-VP16 results in small, pinpoint colonies,
whereas cotransformation of GCN5A and GAL4-VP16 results in slightly larger
colonies, as well as a greater frequency of large colonies that presumably
represent mutant GAL4-VP16 plasmids. (The small colonies do not restreak,
and thus the transformation plates must be scored directly. The difference
between the ability of GCN5 and GCN5A to restore GAL4-VP16 toxicity is
subtle, and may be an artifact of the cotransformation assay. The best way to
compare the ability of GCN5 and GCN5A to restore toxicity would be to express
GAL4-VP16 from an inducible promoter, in the presence of GCN5 or GCN5A.
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However, this has not been done). Thus, in three functional assays, the
bromodomain was important for GCN5 function. To demonstrate that deletion of
the bromodomain did not result in degradation of GCN5, we carried out Western
blot analysis using antibody to the HA epitope (Figure 6). The levels of GCN5
and GCN5A proteins were similar in cell extracts.
The bromodomain could be important in aiding the GCN5-ADA2
interaction, or in facilitating the activity of the assembled ADA complex. To
determine whether the bromodomain was important for the ADA2-GCN5
interaction, we carried out the in vivo and in vitro assays for this interaction with
GCN5A. GCN5A was at least as active as full length GCN5 in the two-hybrid
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Agcn5: :hisG
a/c GCN5A
VECT(
a/c GCN5
211 GCN5
2 L GCN5A
FIGURE 3. GCN5 deleted of the bromodomain (GCN5A) has reducedability to complement a gcn5 deletion. GMy25, a gcn5 deletion strain,was transformed with vector, high copy 2 micron(2p) or low copyARS/cen( a/c) plasmids expressing HA-GCN5 or HA-GCN5A from theADH promoter. Transformants were restreaked on minimal mediumcontaining glucose.
LEX-GCN4 GCN5
LEX-GCN4 GCN5A
-H
LEX-HAP4 GCN5
LEX-NAP4 GCN5A
-HLEX-GAL4 GCN5
LEX-GAL4 GCN5A
0 1000 2000 3000 4000 5000
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FIGURE 4. GCN4 but not HAP4 or GAL4 mediated activation is reduced in a
GCN5 bromodomain deletion mutant (GCN5A). GMy23, a gcn5 deletion strain
was transformed with the lexA activation domain fusions, as well as a second
plasmid expressing GCNSor GCN5LI from the natural GCN5promoter. The
strain also contained the lacZgene under control of a single lexA operator in
plasmid pRbHis. Levels of B-galactosidase were assayed as in Table 2. Error
bars are shown. As an additional control to show that the mutant strain is
indeed defective for trans-activation, the lexA fusions were also assayed in the
same experiment with a vector that did not express any version of GCN5. lexA-
GCN4 gave 151 units, lexA-HAP4 gave 1318 units, and lexA-GAL4 gave 1029
units.
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FIGURE 5. (On the following page) GCN5 deleted of the bromodomain only
partially restores sensitivity to GAL4VP16 toxicity to a gcn5 deletion strain. A.
GMy25 (BP1dgcn5)was doubly transformed with all pairwise combinations of a
high copy plasmid expressing GAL4-VP16 (or the matched URA3 vector control,
pRS426) and a low copy ARS-CEN (a/c) plasmid expressing GCN5 from the
ADH1 promoter (or the matched LEU2 control, pRS315). The transformants
were plated on drop out medium on a single plate. The plasmids are listed next
to the quadrant in which they were plated. B. The transformants here are
identical to those in part A, except that a plasmid expressing GCN5 deleted of
the bromodomain (GCN5A) was used instead of full length GCN5. The severe
growth defect of gcn5 strains observed on minimal medium (FIGURE3a) is not
observed on the supplemented drop out medium after three days. The few
large colonies observed in the GCN5NP16 quadrant result from mutations,
presumably in the GAL4-VP16 expression plasmid. Note that in the
GCN5L/GAL4-VP16 quadrant all transformants grow slightly larger than the
transformants in the GCN5NP16 quadrant, and the frequency of large colonies
is also greater. This should not be considered more than a mild effect.
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FIGURE 6. (On the following page) Western analysis shows similar levels of
GCN5 and GCN5A protein in a gcn5 deletion strain. Western analysis using
12CA5 antibody to the HA epitope (Kolodziej, 1991) was performed on whole
cell extracts of the transformants of GMy25 described in Figure 3a. The bands
corresponding to GCN5 and GCN5A proteins are indicated. A background
protein, found in all extracts, runs directly above the GCN5A band.
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assay (Figure 1). Further, GCN5A was co-precipitated with ADA2 in a manner
similar to GCN5 (Figure2, lanes 1 and 2). Thus, we conclude that the
bromodomain is not an important determinant of the GCN5-ADA2 interaction.
DISCUSSION
We describe an exhaustive application of the selection for mutations
resulting in resistance to GAL4-VP16. We uncovered more alleles of three
genes previously identified, ADA 1, ADA2, and ADA3, and also describe
mutations in two additional genes that arose from the selection, ADA5 and
GCN5. We argued previously that ADA 1 might be mechanistically different from
ADA2 and ADA3 because adal mutants displayed vastly reduced levels of the
toxic chimera, while ada2 and ada3 mutants did not (Berger, et al., 1992).
Mutations in either ADA5 (data not shown) or GCN5 allow accumulation of
GAL4-VP16, suggesting that they are similar to ADA2 and ADA3. The
properties of the gcn5 mutant and the interaction between GCN5 and ADA2 are
the subject of this report.
On the basis of five criteria, we conclude that GCN5 and ADA2 interact
physically and may comprise a part of a multi-protein complex. First, gcn5
mutants display a very similar phenotype to ada2or ada3 mutants. In particular,
strains grow slowly on minimal media, are temperature sensitive on any media,
and greatly reduce trans-activation by the GCN4 and VP16 activation domains,
with smaller effects on the GAL4 and HAP4 activation domains. Second,
doubly null mutants, ada2 gcn5 or ada3 gcn5 do not have a more severe
phenotype than single mutants. Third, lexA-ADA2 and lexA-ADA3 display trans-
activation activities that are dependent upon GCN5. (Other interpretations of
this data are possible. For example, lexA-ADA2 and lexA-ADA3 may contain
cryptic activation domains that are GCN5 dependent, much as the VP16
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activation domain is GCN5 dependent. However, given the other evidence for
an ADA2/GCN5 interaction, and the utility of lexA fusions to study interactions
among HAP2, HAP3, and HAP4 (Olesen and Guarente, 1990), as well as
SNF2,SNF5 and SNF6 (Laurent and Carlson, 1992), it is reasonable to argue
that the activity of lexA-ADA2 and lexA-ADA3 represent the activity of an ADA
complex). Fourth, ADA2 and GCN5 show a strong interaction in vivo by two-
hybrid analysis. Fifth, ADA2 and GCN5 co-precipitate. This final experiment
suggests that the interaction between the two proteins is direct and requires no
other yeast proteins. Furthermore, recent experiments have shown that GCN5
cofractionates with affinity purified ADA2 protein from yeast extracts (N.
Silverman, unpublished results).
Thus, we envision a complex containing these two proteins and perhaps
ADA3, and ADA5. There may be additional factors in this set among those
strains that are resistent to GAL4-VP16 that have not yet been characterized.
Several other multi-protein complexes have been shown to play a role in
eukaryotic transcription. The SWI/, SWI2/SNF2, SW13, SNF5 and SNF6
genes are important for transcription of many yeast genes. They were first
classified together genetically (Winston and Carlson, 1992) and now have been
shown to comprise a complex (Cairns, et al., 1994; Peterson, et al., 1994).
These factors are evidently important for activity of the glucocorticoid receptor in
yeast (Yoshinaga, et al., 1992), and they promote the binding of GAL4
derivatives to nucleosomal DNA in vitro (Verrijzer, et al., 1994). Similarly, the
SRB genes interact genetically with the C-terminal domain (CTD) of the largest
subunit of RNA polymerase II (Thompson, et al., 1993). The products of these
genes form a complex that co-fractionates with RNA polymerase II and comprise
an RNA pol II holoenzyme that also includes TFIIB, the 73K subunit of TFIIH ,
and TFIIF (Koleske and Young, 1994). A third complex may involve products of
some SPT genes, identified as suppressors of TY1 insertions in yeast
promoters (Winston, et al., 1984). Based on the similarity of SPT3, 7, 8, and 15
mutants, it is possible that the products of these genes comprise a complex
(Winston, 1992). In fact, SPT3 and TBP, the tata binding protein, which is the
SPT15 product, have been shown to interact (Eisenmann, et al., 1992). In
Drosophilla and mammalian cells, TBP is a part of a multi-protein complex,
TFIID, which also contains TBP associated factors (TAFs) (Dynlacht, et al.,
1991).
What is the role of the ADA2-GCN5 complex? We have suggested that
ADA2 and ADA3 might be transcriptional adaptors which help bridge the
interaction between activators and the basal factors. Consistent with this
hypothesis, expression of an epitope tagged version of ADA2 in yeast allows
co-precipitation of the tagged ADA2 protein and GAL4-VP16 in yeast extracts
(N. Silverman, J. Agapite, and L.G., submitted; R. Candau, N. Bordei, D.
Darpino, L. Wang, and S.B., unpublished data). We surmise that the
ADA/GCN5 complex also contains domains that interact with one or more of the
basal factors.
One domain that is a candidate for such interactions is the bromodomain,
found at the carboxyl-terminus of GCN5, and also in the mammalian TAF
complex, the SNF complex, the E1A associated p300 (Goodrich and Tjian,
1994), and in several factors in Drosophila, such as brahma (Kennison, 1993).
In several cases, deletion of the bromodomain was shown to be
inconsequential (Laurent, et al., 1993) (Elfring, et al., 1994) (Gansheroff, et al.,
1995).
Here, we show that deletion of the bromodomain does not lower the
steady-state levels of GCN5, but does reduce the ability of the protein to
complement a gcn5deletion strain and to support the activity of the GCN4
activation domain. In addition, the truncated protein only partially restores
toxicity by GAL4-VP16 compared to the full length GCN5. We have previously
proposed that toxicity was due to trapping of basal factors by the potent VP16
activation domain at chromosomal sites (Berger, et al., 1992). The
bromodomain may be important in this process by helping the ADA complex
bind to activation domains to basal factors, or to DNA.
Although it is also possible that the bromodomain helps interactions
within the ADA complex, we do not favor this possibility for two reasons. First,
the bromo-deleted GCN5 interacts with ADA2 in the two-hybrid and co-
precipitation assays as well as the full length GCN5 does. Second, the fact that
the domain is present in proteins found in other transcription complexes
suggests that its function is more general. We infer that the function of the
bromodomain is partially redundant in the ADA complex, because the truncated
protein still has a partial ability to function. The function of the bromodomain
may be redundant in other complexes in which it could be deleted without
impairing activity.
In summary, we show that our genetic selection has converged on at
least two proteins, ADA2 and GCN5, that function together by virtue of
comprising a heteromeric complex. The importance of such complexes in
transcription is just now coming to light. The precise molecular function of this
complex and the activity of the bromodomain in particular, should bring further
understanding to the process of eukaryotic transcriptional activation.
MATERIALS and METHODS
Selection of GAL4-VP16 Resistant Mutants
pGAL4-VP16 URA was generated by ligating a 2.8 KB. BamHI fragment
from pSB201 (Berger, et al., 1992) containing the ADH promoter/terminator
cassette with GAL4-VP16 into the BamHI site of pRS426 (Sikorski and Hieter,
1989).
The strain BP1 (MAT a, adel-100, ura3-52, leu2-3,2-112, his4-519) was
mutagenized with EMS (Guthrie and Fink, 1991), grown for 5 hours in YPD, and
then transformed with the 2p plasmid pGAL4-VP16 URA, and plated on the rich
medium sd+ 0.1%case amino acids, 0.006%adenine, 2% glucose. 300,000
primary transformants were screened, the majority of which were tiny, pinpoint
colonies. 300 larger colonies were picked and restreaked. Candidate strains
with the toxic plasmid were mated to PSY316 (MATa, ade2-101, ura3-52, leu2-
3,2-112, his3-del.200, lys2), a wild type tester strain, and diploids that retained
the plasmid with GAL4-VP16 were selected. Diploid strains that regained
sensitivity to the toxic plasmid were obtained when the original haploid strain
contained a recessive mutation that gave resistance to GAL4-VP16. The other
strains were presumed to have a dominant chromosomal mutation or a mutation
in the GAL4-VP16 expression plasmid. These strains were cured of the plasmid
by growth on FOA, and mated to strain NSy5B (MATa, ade2-101, ura3-52, leu2-
3,2-112ada2-2, his-) containing pGAL4-VP16URA. None of the resulting
diploids were clearly resistant to the toxic plasmid, implying that all 250 of these
strains had mutations linked to the plasmid. The strains with recessive
mutations were mated to ada1-, ada2-, or ada3- tester strains to identify
additional alleles of these genes by complementation of the slow growth and
toxicity resistance phenotypes. ADA4 and ADA5 complementation groups were
identified among the remaining resistant strains using a segregant that was
obtained during tetrad dissection. Additional strains resistant to GAL4-VP16
were isolated that do not conform to these complementation groups. In most
cases this is because they lack secondary phenotypes or appeared to have
multiple mutations responsible for the slow growth phenotype. We also isolated
74
1 sterile strain that conferred resistance to GAL4-VP16. However, no GAL4-
VP16 protein was detected (not shown).
Cloning and Sequencing of GCN5
GMy47c (BP1 gcn5-1) was transformed with a yeast genomic library
(Thompson, et al., 1993) and colonies which grew well on minimal media were
selected. From these, we isolated a clone, p15-1,2c with a 12KB insert that
restored wild type growth and sensitivity to GAL4-VP16 to GMy47c, as well as to
strains with gcn5-2, or gcn5-3 alleles. 15-1,2c was partially digested with
Sau3a, the DNA was run on a 1.2% agarose gel, and a band was cut out with
fragments ranging from 1-3KB. The DNA was gene cleaned (Bio 101) and
ligated into pRS316 cut with BamHl to generate a sub-genomic library. GMy47c
was transformed with the subgenomic library, and a 2.2KB subclone, p5-1,2D,
was isolated from a fast growing colony that restored wild type growth and
sensitivity to GAL4-VP16 to GMy47c. Restriction analysis later revealed that 5-
1,2D is in its CT3, the vector of 15-1,2c and not in pRS 316. Thus, the subclone
is an internal deletion of almost 10KB from the insert of 15-1,2C.
The ends of the insert in 5-1,2D were sequenced using the Sequenase
kit (USB) using the T3 and -20 primers. The DNA sequences were analyzed
using the Blast program (Altschul, et al., 1990), and the sequence from the -20
primer matched the yeast sequence for the PUP2 gene (Georgatsou, et al.,
1992), which lies adjacent to GCN5
GCN5 Plasmids
pRS316 GCN5 was generated by cutting p5-1,2D with PsfI, blunting with
T4 polymerase, and cutting again with Xhol to get a 1.8 KB. fragment. This was
75
cloned into pRS 316 cut with Xhol and Smal. This same 1.8 KB. fragment was
cloned into pRS 306 cut with Xhol and Smal to generate pRS306 GCN5.
The PCR generated fragments were cut with Notl and cloned into a high
copy vector (DB20L) or a low copy vector (RK15) to generate the following ADH
expression plasmids: pDB20LGCN5 (using primers GCN5N and GCN5C,
Table 4), pDB20LGCN5A (using primers GCN5N and GCN5CA, Table 4),
pDB20LHA-GCN5 (using primers NHAGCN5N and GCN5C, Table 4),
pDB20LHA-GCN5A (using primers NHAGCN5N and GCN5CA, Table 4). PCR
primers are listed in Table 4. The same fragments were ligated into the Notl site
of pRK15 (an ARS/cen ADH expression plasmid based on pRS315 R.Knaus,
unpublished data) to generate pRKGCN5, etc.
pRS315GCN5 was generated by cloning a 1.8 KB Xhol EcoRV fragment
containing the GCN5 gene from pSP72 GCN5 (see below) into the Xhol -
blunted BamHI site of pRS 315(Sikorski and Hieter, 1989). pRS315GCN5A
was generated by removing most of the GCN5 coding sequence from
pRS315GCN5 by cleaving at the unique HindIll (which cuts 15 base pairs after
the stop codon) , filling in the ends with the Klenow fragment of DNA
polymerase, and then cleaving with BamHI, which cuts 50 base pairs after the
start codon. The remainder of the coding sequence for GCN5A was supplied by
cutting pRKHAGCN5A with Notl to release the GCN5A insert, treating with the
Klenow fragment of DNA polymerase to blunt the ends, and cutting with BamHl.
lexA and VP16 fusion plasmids:
plexA-ADA2 was generated by amplifying the ADA2 gene using primers
ADA2LN, AND ADA2LC (Table 4), cutting with Notl, and ligating in frame to the
Notl site of pADHlexA202 (a 2pplasmid). plexA-ADA3 was generated the same
way except primers ADA3N and ADA3CNOT (Table 4) were used to amplify
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ADA3. plexA-GCN5 and plexAGCN5A were generated the same way except
that primers GCN5N and GCN5C or GCN5CA (Table 4) were used to amplify
GCN5 and GCN5A respectively. All three lexA fusions were able to
complement the slow growth and toxicity phenotypes in the appropriate ada
mutant strains (data not shown). lexAGCN5A was able to complement GMy25
as well as pRKHA-GCN5A.
The ADA2VP16 plasmid was generated in two steps. ADA2 was
amplified using primers ADA2PRON and ADA2CNOT (Table 4), cut with Hindlll
and cloned into the Hindlll site of pRK25 (a 2p ADH expression plasmid based
on pRS425 R.Knaus, unpublished data) to generate pRK25ADA2CNOT. Then,
the bases encoding residues 452-490 of VP16 were amplified by PCR using
primers V452N and VP16C (Table 4), cut with Notl, and cloned into
pRK25ADA2CNOT cut with Notl, which fuses VP16 452-490 in frame with the C-
term of ADA2, to generate pRK25ADA2VP16.
The lexA His reporter pRBHis (gift of John Fikes) was generated by
cutting Rb1155 (Brent and Ptashne, 1985)with Stul to excise the URA3 gene
filling in with the DNA polymerase Klenow fragment, and ligating the HIS4
fragment from pB54 (Donahue, et al., 1982).
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TABLE 4 (Following page)
LEGEND. PCR Primers. Primers were synthesized at the Biopolymers
Laboratory, Howard Hughes Medical Institute, Center For Cancer Research,
Department of Biology, MIT. 50 pMol of each primer was used for each PCR
reaction.
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TABLE4: PCR Primers
SEQUENCE
GCN5N
GCN5C
GCN5CA
GCN5AADC
NHAGCN5
ADA2LN
ADA2LC
ADA2proN
ADA2CNOT
ADA3N
ADA3CNOT
V452N
VP16C
CCCGGGAGATCTGCGGCCGCGATGGTCACAAAACATCAG
GAACCCCGGGGCGGCCGCCTAAGATCTTCAATAAGGTGAGAATA
TTC
GGCCCGGGGCGGCCGCCTAAGATCTTGCTGCATGATTTTGTAGC
CCCGGGAGATCTCTAAGAGGCCGCTCAATAAGGTGAGAATATTC
CCCGGGGCGGCCGCATGCTTACCCATACGACGTCCCAGACTACG
CCATGGTCACAAAACATCAGATTG
GGGCCGCGGCCGCATGTCAAACAAGTTTCACTGTGAC
GGGCCGCGGCCGCTTACATCCAATTCTGGCTCTGGAA
GGGCCCGGAAGCTTCATGAGCAACAAGTTTCACTGTGACGTTTG
CCCGGGAAGCTTAAGCGGCCGCCATCCAATTCTGGCTCTGG
CCCGGGGCGGCCGCTGGATCCATGCCTAGACATGGAAGAAGAGG
CCCGGGTGCGGCCGCTTAATTTAGTTCCACGTCC
CCCGGGGCGGCCGCGTCCCCGGGTCCGGGATTTACC
CCCGGGATCCGCGGCCGCTACCCACCGTACTCGTCAATTCC
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Deletion Plasmids and Strains:
The GCN5 deletion plasmid was generated in several steps. First, the
BamHI site in pSP72 (Promega) was destroyed by cutting, filling in using the
DNA polymerase Klenow fragment, and ligation to generate pSP72-Bam. Next,
the 1.8KB Xhol-Psfl fragment from 5-1,2D, containing GCN5 and flanking
sequence was cloned into the Xhol-Psfl sites of pSP72-Bam to generate pSP72
GCN5. The GCN5 coding sequence was removed by ligating a BamHI linker to
a filled in Hindlll site, followed by digestion with BamHI. This served as the
backbone to which the 2.4 KB. BamHI-BgAli hisG Ura3 cassette from pNKY51
(Alani, et al., 1987) was ligated, to generate pGCN5KO.
The ADA3 deletion plasmid was generated in several steps also. A
2.9KB Xbal-Psft fragment containing ADA3 and flanking sequences was cut
from the genomic clone pADA3HHV (Piia, et al., 1993) and ligated into the Xbal
Pstl sites of pSP65 (Promega) to generate pSP65 ADA3. A Ndel-Spel fragment
encoding the first 588 amino acids of the ADA3 protein was removed from this
plasmid. The ends were filled in with DNA polymerase Klenow fragment,
ligated with Bglll linkers, and cut with Bglll. The 2.4 KB. BamHI-BgAl hisG URA3
cassette (Alani, et al., 1987) was ligated into this bacKbone to generate
pADA3KO.
GCN5 deletion strains were generated by transforming yeast with 10 pg
of GCN5KO cut with Xhol-Sal. Slow growing Ura+ transformants were tested
for resistance to GAL4-VP16, and to see if wild type growth was restored by
DB20L GCN5. Strains that were resistant to GAL4-VP16 and had wild type
growth restored by the clone were streaked on 5-fluoroorotic acid (FOA) to
select strains that had looped out the URA3 sequence. In this manner, Ura+
and ura- deletion strains GMy22 and GMy23 were generated from BWG1-7a;
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GMy24 and GMy25 from BP1; and GMy26 and GMy27 from PSY316. 1-
7adada2Lgcn5 was constructed by transforming GMy23 with ADA2KO (Berger,
et al., 1992) cut with BamHI and Xhol. Transformants were isolated, tested by
mating, grown in YPD broth and plated on medium containing FOA to select
strains that had excised the URA3 gene from the hisG cassette. The genotype
of the strains were confirmed transformation with the ADA2 and GCN5 clones.
GMy28 (BWG1-7aAada3Agcn5) was constructed in a similar manner
except that GMy23 was transformed with pADA3KO plasmid cut with Pvull and
BamHI. Double mutants were confirmed by mating and by transforming with the
ADA3 and GCN5 clones.
PSY316GCN5 was generated by transforming PSY316 with
pRS306GCN5 cut with Hindlll to target the GCN5 locus. This strain was mated
to GMy47c (BP1, gcn5-1). The resulting diploid was sporulated and tetrads
were discected.
ADA2 anti-sera.
The ADA2 coding sequence engineered with a BspHI site at the ATG, 6
Histidines at the C-terminus, as well as flanking Hindlll sites was generated
using PCR and primers ADA2PROC and ADA2PRON (Table 4). This PCR
product was cloned into pRK16 (gift of R. Knaus) as a Hindlll fragment and
checked for complementation in yeast. Then, the gene was isolated on a
BspHIIHindlll fragment and cloned in a Ncol and Hindlll digested
pUH24.2ACAT. This vector was contructed by modifying the expression vector
pDS56/RBSII, Ncol (gift of D. StOber, identical to pQE-7 from Qiagen) by cutting
with Bsml and religating, leaving a unique Ncol site. The ADA2 bacterial
expression vector, pA26HE produced large amounts of ADA2 protein which
was insoluble. Denaturing Ni-bead chromotography (Qiagen) was used to
purify this protein.
Purified ADA2 protein (0.5-1.0mg/ml in Saline) was mixed with RIBI
adjuvant (RIBI ImmunoChem Research, Inc.) and used to immunize two rabbits
per standard protocol (Harlow, 1988). After several boosts crude sera was
assayed for anti-ADA2 antibodies by Western blot analysys. It was
demonstrated that one rabbit produced a good titter of anti-ADA2 sera by virtue
of its ability to recognize ADA2 protein in E. coli extracts from strains with
pA26HE, but not in control extracts. ADA2 protein could also be detected in
yeast extracts from strains overexpressing ADA2 (data not shown).
In vitro transcription/translation
To generate GCN5 RNA the transcription plasmid pT7GCN5 was
generated by amplifying GCN5 with the primers GCN5N and GCN5AADC
(Table 4), cutting with BgAl, and ligating into the BamHI site of T7Plink (Dalton
and Treisman, 1992). pT7GCN5A was generated in the same way except the
PCR fragment was amplified using the GCN5CA oligo (Table 4) instead of the
GCN5AADC oligo. pT7ADA2 was generated by ligating the BspHII-BgAll
fragment from pA2HA (Silverman, Agapite and Guarente, in preparation) into
the Ncol-BamHl sites of T7Plink.
Transcription reactions were carried out using 2.5pg of T7GCN5 or
T7GCN5A linearized with Xhol in 1X T7buffer (GIBCO BRL). Trace amounts of
rUTP were included in the reaction to measure percent incorporation. RNA
pellets were resuspended in H20 at .4pg/pl. Translations were carried out in
25p1 reactions with .6pg of each RNA following the standare protocol of the
Nuclease Treated Lysate (Promega). The -met amino acid mix was used, and
35S methionine (Amersham) was incorporated in the proteins produced.
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Immunoprecipitation
Protein A Sepharose beads (CL-4b Sigma) were pre-equilibrated
overnight in IP buffer (10% Glycerol, 50mM Hepes KOH pH 7.3, 100mM K
glutamate, 0.5mM DTT, 6mM MgOAc, 1mM EGTA, 0.1% NP40 and .5mg/ml
BSA). 20pl of bead slurry were spun in a microfuge, and the beads were
resupeneded in 20pl fresh IP Buffer. 5pl retic lysate containing translated
proteins and 1pl anti-ADA2 sera were added to the beads, mixed, and rotated 3
hrs at 40. The reactions were then spun 2 min. at 7k and the supernatant was
removed. The beads were washed three times with iml IP buffer by inverting
and vortexing. Following the last wash, the supernatent was removed and the
pellets were resuspended in 20pl loading dye (Maniatis). Samples were boiled
3 min, vortexed, and boiled again 3 min prior to loading on 10% SDS PAGE
gels. The dried gel was exposed overnight on Hyperfilm-ECL (Amersham).
Yeast Manipulations, Media, Westerns and B-galactosidase assays.
Transformations were by the LiOAc method (Gietz, et al., 1992). Tetrad
analysis and other yeast manipulations were done using standard techniques
(Guthrie and Fink, 1991). 13-galactosidase assays were carried out on yeast
extracts made from breaking cells with glass beads (Rose and Botstein, 1983).
The activity of 3-galactosidase is normalized to total protein. Westerns were
performed using standard protocols(Harlow, 1988). Slow growth phenotypes of
ada mutants were assayed on SD minimal medium supplemented with amino
acids and adenine. Otherwise strains were grown in SD rich drop out medium
containing all amino acids except those needed for plasmid selection.
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Chapter 3
GCN5 Cofractionates With ADA2 and ADA3, and Regulates
lexA-ADA2 In An ADA3 Independent Manner
INTRODUCTION
Activation in eukaryotes requires two types of DNA elements, and three
classes of transcription factor. Basal factors bind to the TATA box, proximal to
the site of transcriptional initiation. Activators bind to the distal UAS/enhanser
element and stimultate activation. Coactivators, the third class of transcription
factor, are necesary for activated but not basal transcription and mediate the
interaction between activators and basal factors (Berger, et al., 1990; Pugh and
Tjian, 1990).
Coactivators can bind activators in at least two different ways. Some
coactivators only bind to certain activation domains. For example, TAF110
interacts with the glutamine rich activation domain SP1 but not the acidic
activation domain VP16 (Hoey, et al., 1993). Conversely, TAF60 binds VP16
but not SP1 (Thut, et al., 1995). Both TAF110 and TAF60 are part of a
coactivator complex associated with TBP that can respond to either SP1 or
VP16 (Goodrich and Tjian, 1994). Subcomplexes lacking TAF110 are not
activated by SP1, and subcomplexes lacking TAF60 do not respond to VP16,
indicating that the activator-coactivator interaction determines the specifity for
coactivator activity (Chen, et al., 1994). Other coactivators such as PC4/p15 can
bind to, and stimulate activation from a number of different types of activator (Ge
and Roeder, 1994; Kretzschmar, et al., 1994).
In addition, it is possible to bypass the need for an activator by fusing a
coactivator directly to a DNA binding domain. For example, the coactivator CBP
fused to the GAL4 DNA binding domain can stimulate a GAL reporter when
transfected into cells (Kwok, et al., 1994). The yeast coactivator GAL1 1 also
activated when fused to a DNA binding domain (Himmelfarb, et al., 1990).
Similarly, the yeast SNF2/SWI2, SNF5 or SNF6 activate transcription when
fused to the lexA DNA binding domain (Laurent, et al., 1991). SNF2/SWI2,
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SNF5 and SNF6 are part of a large, multisubunit complex that antagonizes
histone repression in vivo and in vitro (Cote, et al., 1994; Hirschhorn, et al.,
1992). The activity of the lexA-SNF2 and lexA-SNF5 fusions decreases in
swi/snf mutants strains, which supports the notion that the activity of these
fusions depends on the integrity of the SWI/SNF complex in vivo (Carlson and
Laurent, 1994).
ADA2, ADA3 and GCN5 were isolated in a selection for mutants resistant
to GAL4-VP16 mediated toxicity (Berger, et al., 1992; Marcus, et al., 1994).
These genes have been proposed to be coactivators because mutants in any of
these strains are unable to support activation from the VP16 or GCN4 activation
domains in vivo or in vitro (Berger, et al., 1992; Marcus, et al., 1994; Pima, et al.,
1993). Other activation domains, such as HAP4 and GAL4 activate
independently of ADA2, ADA3 and GCN5 (Berger, et al., 1992; Marcus, et al.,
1994; Pima, et al., 1993). Moreover, the ADA2, ADA3 and GCN5 proteins can
form a complex in vitro, and may act as a complex in vivo by genetic criteria
(Horiuchi, et al., 1995; Marcus, et al., 1994). The specifity of the ADA2 complex
may be governed by the binding of ADA2 to activation domains. ADA2 can bind
VP16 and GCN4 (Barlev, et al., 1995; Silverman, et al., 1994), but does not bind
HAP4 or GAL4 (Barlev, et al., 1995).
Like CBP, GAL1 1 and components of the SWI/SNF complex, ADA2 and
ADA3 can activate transcription when fused to a DNA binding domain (Marcus,
et al., 1994). The activity of lexA-ADA2 can be modulated by increasing or
decreasing the level of ADA3 in the cell. lexA-ADA2 does not activate well in
ada3 mutants, but activates extremely well when ADA3 is overexpressed
(Silverman, et al., 1994). The activity of lexA-ADA3 is similarly effected by the
level of ADA2 in the cell (Horiuchi, et al., 1995). Neither lexA-ADA2 nor lexA-
ADA3 can activate in gcn5 mutants (Marcus, et al., 1994). Together, this argues
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that fusing ADA2 or ADA3 to a DNA binding domain is bypassing the need for
an activator, allowing the ADA complex to activate directly.
Here, we show that the activity of lexA-ADA2 is superactivated by ADA2
overexpression, and superrepressed by GCN5 overexpression. Further,
superrepression occurs in an ada3 deletion mutant, suggesting that ADA2 and
GCN5 can associate in vivo in the absence of ADA3. Additionally, we show that
GCN5 co-fractionates with ADA2 and ADA3 from yeast extracts. Finally, we
report the identification of a human cDNA that encodes a protein with high
sequence similarity to GCN5.
RESULTS
The ability of lexA-ADA2 to activate transcription is modulated by
overexpression of ADA2 and GCN5
Previously, we have observed that the activity of lexA-ADA2 is
superactivated by overexpression of ADA3, and the activity of lexA-ADA3 is
superactivated by overexpression of ADA2 (Horiuchi, et al., 1995; Silverman, et
al., 1994). Given these results, we took a more systematic approach to
investigate the effect of overexpressing ADA genes on the activity of lexA-ADA
fusions. lexA-ADA2, lexA-ADA3 and lexA-GCN5 were tested for their ability to
activate transcription alone, or when one of the ADA genes is overexpressed.
As shown in Table 1, the activity of lexA-ADA2 moiety is superactivated over
three fold when ADA3 is overexpressed, and similarly, the activity of lexA-ADA3
is superactivated three fold by overexpression of ADA2 This is in agreement
with previous observations, and suggests that either ADA2 or ADA3 is limiting
for trans-activation when the other is overexpressed as a lexA fusion (Horiuchi,
et al., 1995; Silverman, et al., 1994).
TABLE 1 (Following page)
LEGEND. The wildtype strain BWG1-7a containing pRbHis (Marcus, et al.,
1994), a plasmid with the 8-galactosidase gene under the control of a lexA
operator, was doubly transformed with all pairwise combinations of plexA-
ADA2, plexA-ADA3 or plexA-GCN5 as the first plasmid (Marcus, et al., 1994),
and pDB20LADA2 (Marcus, et al., 1994), pDB20LADA3 (Silverman, et al.,
1994), pDB20LGCN5 (Marcus, et al., 1994) or pDB20L as the second plasmid.
pDB20L is a 2p plasmid used to overexpress genes from the strong constitutive
ADH1 promoter (Becker, 1991). The specific activity of 1-galactosidase
averaged from at least three independant experiments is presented (SD<20%)
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Surprisingly, the activity of lexA-ADA2 can also be modulated by
overexpression of either ADA2 itself or GCN5. lexA-ADA2 is superactivated
four fold by ADA2 overexpression. In contrast, the activity of lexA-ADA2 is
superrepressed four fold by overexpression of GCN5. The superactivation may
be related to possible multimerization by ADA2, and the superrepression may
result from saturation of a binding site on a basal factor by GCN5 (see
Discussion). In addition, although lexA-GCN5 only activates very weakly, its
activity increases two fold when ADA2 or ADA3 is overexpressed. Importantly,
the superactivation and superepression effects are specific to certain lexA-
fusions. The activity of lexA-ADA3 is unaffected by overexpression of either
ADA3 or GCN5. Furthermore, we have previously shown that the activity of true
activators such as lexA-GCN4 or lexA-HAP4 is not altered by overexpression of
ADA2 or ADA3 (Horiuchi, et al., 1995; Silverman, et al., 1994). The activity of
lexA-GCN4 is also unchanged when GCN5 is overexpressed (Table 2).
The observation that the activity of lexA-ADA2 can be modulated by
overexpression of ADA2 or GCN5 is novel. Therefore, we wished to determine
whether superactivation and superrepression depend on the copy number of
the lexA-ADA2 protein. As shown in Table 2, lexA-ADA2 expressed from a low
copy ARS-CEN plasmid is less active than 2p (high copy) lexA-ADA2, and is
still superactivated by ADA2 overexpression and superrepressed by GCN5
overexpression.
Previously, we have argued that the activity of lexA-ADA2 represents the
activity of the ADA2, ADA3 and GCN5 complex. The activity of lexA-ADA2
decreases in ada3 or gcn5 mutants, suggesting that the complex is disrupted
(Marcus, et al., 1994; Silverman, et al., 1994). We have also shown that ADA2
and GCN5 can interact in vitro in the absence of ADA3 (Marcus, et al., 1994). If
superrepression requires the integrity of the ADA2 complex in vivo, than GCN5
TABLE 2 (Following page)
LEGEND. The wildtype strain BWG1-7a containing pRbHis, a plasmid with the
B-galactosidase gene under the control of a lexA operator, was doubly
transformed with all pairwise combinations of plexA-ADA2, or plexA-ADA2 a/c
as the first plasmid, and pDB20LADA2, , pDB20LGCN5, pDB20LGCN5L or
pDB20L as the second plasmid. pDB20LGCN5 expresses a varient of GCN5
with the bromodomain deleted (Marcus, et al., 1994). In addition, plexA-ADA3,
or plexA-GCN4 were also transformed with pDB20LGCN5 or pDB20L. The
specific activity of B-galactosidase averaged from at least three independant
experiments is presented (SD<20%). n.d. indicates the experiment was not
performed.
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should not be able to superrepress lexA-ADA2 in an ada3 deletion strain.
However, if superrepression only depends upon the ADA2-GCN5 interaction,
then GCN5 should be able to superrepress in an ada3 deletion strain. As
shown in Table 3, although the activity of lexA-ADA2 is three fold lower in the
ada3 deletion strain, it is still superrepressed by GCN5. This shows that
superrepression reflects the ADA2-GCN5 interaction and not a destablization of
the ADA complex. Further, it argues that ADA2 and GCN5 can associate in vivo
in the absence of ADA3.
The bromodomain of GCN5 contributes to growth and GCN4 activation in
vivo, and does not mediate the ADA2-GCN5 interaction (Marcus, et al., 1994).
Because the bromodomain is conserved in many different coactivators, it may
interact with a component of the basal machinery. Conceivably, the
bromodomain could be necessary for superrepression. As shown in Table 2,
however, a GCN5 bromodomain deletion mutant (GCN5A) can still
superrepress. Thus, the putative interaction between the bromodomain and
another factor is unnecessary for superrepression.
GCN5 shows the same elution profile as ADA2 and ADA3 during
purification.
The superrepresion of lexA-ADA2 by GCN5 adds to a large body of
evidence arguing that ADA2, ADA3 and GCN5 act as a complex in vivo. ADA2
and GCN5 interact by two hybrid analysis (Marcus, et al., 1994); in vitro
translated ADA2, ADA3 and GCN5 co-immunoprecipitate as a complex
(Horiuchi, et al., 1995); and ada2ada3, ada2gcn5 and ada3gcn5 double
deletion mutants have phenotypes no more severe than single mutant
phenotypes, a strong indication that they act as a complex or the the same
pathway in vivo (Marcus, et al., 1994; Piia, et al., 1993).
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TABLE 3 (Following page)
LEGEND. BWG1-7a (wildtype) or 1-7aAada3(Aada3) (Pifa, et al., 1993), each
containing pRbHis were transformed with plexA-ADA2 and pDB20LADA3,
pDB20LGCN5 or pDB20L. The specific activity of 3-galactosidase averaged
from at least three independant experiments is presented (SD<20%).
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In addition, unpublished experiments by Silverman and Guarente have
shown that ADA2 and ADA3 copurity from yeast extracts through four columns
(see Methods for more details of the purification). A nickel column is used in the
second step to affinity purify ADA2, which is tagged with six histidine residues.
To determine if GCN5 is copurifying with ADA2 and ADA3, protein fractions from
each stage of the purification were assayed for GCN5 by Western analysis
using aGCN5 antiserum. GCN5 and ADA3 show an identical elution profile
through the first two purification steps (Figure 1 top). Both proteins are retained
on the Bio-Rex70 column and elute in 600mM and 1200mM potassium acetate.
Moreover, six-his tagged ADA2 is retained on the nickel column (N. Silverman,
unpublished data), as well as ADA3 and GCN5 (Figure 1 top, 6N and 12N).
Importantly, GCN5 also co-purifies through two additional chromatography
steps with ADA2 and ADA3 (data not shown). In summary, ADA2, ADA3 and
GCN5 show identical elution profiles through four chromotagraphy steps that
give a 300 fold purification (data not shown), arguing that these genes are part
of a complex in vivo.
ADA2 and ADA3 also copurify over four columns in a different
fractionation system (see methods). Three fractions that cross the ADA2/ADA3
peak on Heparin column were assayed for GCN5 by Western blot analysis
using GCN5 antiserum. As shown in Figure 1 (bottom), GCN5 peaks in fraction
21, which is the peak of both ADA2 and ADA3 (data not shown). Thus, ADA2,
ADA3 and GCN5 show the same elution profile after four purification steps in
this second fractionation, which along with the first purification, indicates that
they are part of the same complex in vivo.
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FIGURE 1. (Following page). GCN5 copurifies with ADA3. Whole cell
yeast extracts were chromatographed on a Bio-Rex 70 column. Proteins were
stepwise eluted in 250 mM, 600 mM and 1200 mM potassium acetate. 100 pg
of the whole cell extract (WCE) and flow through (FT), and 50 pg of each elution
were assayed for GCN5 and ADA3 by Western blot analysis. "250" is the
250mM elution, "6" is the 600 mM elution, and "12" is the 1200 mM elution from
the Bio-Rex 70 column. "6Ni" and "12Ni" are the 600 mM and 1200 mM
fractions after an additional purification on a nickel column, which should retain
the six His tagged ADA2 (see Methods).
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Fraction WCE FT 250
Lane 1 2 3
16 6Nil1 2 12Ni
4 5 6 7
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Fraction 16 19 22
ADA3
GCN5
GCN5
Identification of a putative human homolog of GCN5
The growing library of expressed sequence tags (EST) is a useful
reagent to identify mammalian homologs of yeast genes by amino acid
similarity. Using the XREFdb database, we identified three independent ESTs
from humans with regions of overlapping DNA sequence (Reeves, et al., 1995).
The similarity between the protein sequence of the largest cDNA is compared to
GCN5 in Figure 2. Over these two closely spaced regions, there is 66% amino
acid identity and 80% amino acid similarity. This homology is located in the N-
terminal half of GCN5, and does not contain the highly conserved bromodomain
that has been found in many proteins. The high degree of sequence similarity
makes this an excellent candidate to be a human homolog of GCN5. However,
isolation of the entire cDNA, followed by functional analysis will be necessary to
confirm this.
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FIGURE 2 (Following page). GCN5 and a human cDNA share 66% amino acid
identity and 80% amino acid similarity. A human cDNA (Accession number
H38810) homologous to GCN5 was identified from the XREFdb database
(Reeves, et al., 1995).
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DISCUSSION
Previously, we have argued that the ability of lexA-ADA2 and lexA-ADA3
to trans-activate in an ADA dependent manner reflects the activity of the ADA
complex (Marcus, et al., 1994). The superactivation of lexA-ADA2 by ADA3,
and of lexA-ADA3 by ADA2 suggest that when one is overexpressed as a lexA-
fusion, the other is limiting, and thus overexpression of both proteins gives
maximal trans-activation (Horiuchi, et al., 1995; Silverman, et al., 1994). Here,
we have shown that the activity of lexA-ADA2 can be superactivated by ADA2
overexpression, and super-repressed by GCN5 overexpression. (This is in
contrast to published reports by others, who show that lexA-ADA2 can be
superactivated by GCN5 overexpression, and super-repressed by ADA2
overexpression (Georgakopoulos, et al., 1995). This may reflect differences in
strains, the lexA-ADA2 fusions, or the use of a lex a reporter with one site in this
study, and eight sites in the other study).
Superactivation may result from multimerization of ADA2 with lexA-
ADA2. This would create a larger surface to interact with basal factor targets
and thus activate at a higher rate. Multimerization of weak activation domains
give rise to more powerful activation domains (Seipel, 1992). Furthermore, the
human activator SP1 can be superactivated by its own activation domain, or by
TAF110, a coactivator for SP1 activation (Courey, et al., 1989; Hoey, et al.,
1993). The SP1 superactivation is mediated by multimerization (Pascal and
Tjian, 1991). Multimerization may also involve the entire ADA2 complex. Since
ADA2 can serve as a linchpin between ADA3 and GCN5 in vitro (Horiuchi, et
al., 1995), it may be well suited to nucleate the formation of multimeric ADA
complexes. Alternatively, superactivation may proceed by titration of a negative
regulator of ADA2. There are at present no candidates for this negative factor.
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One way to explain the superrepression of lexA-ADA2 by GCN5 is to
assume the activity of lexA-ADA2 reflects the activity of a lexA-ADA2, ADA3 and
GCN5 complex. If GCN5 mediates the interaction between this complex and
basal factors, than excess GCN5 could be binding to the basal factors, blocking
access by the lexA-ADA2/ADA3/GCN5 complex. It is unlikely that GCN5 serves
as a negative regulator of ADA2 because trans-activation by lexA-ADA2 as well
as real activation domains is reduced in GCN5 mutants (Georgakopoulos and
Thireos, 1992; Marcus, et al., 1994). Finally, GCN5does not superrepress lexA-
ADA3, lexA-GCN4 and can still superrepress lexA-ADA2 in an ada3 mutant
strain. Thus, whatever its mechanism, superrepression reflects the specific
interaction between ADA2 and GCN5.
In addition, there is a strong correlation between superactivation or
superrepression in vivo, and protein protein interactions in vitro. In particular,
ADA2 can bind ADA3, and ADA2 and ADA3 can superactivate lexA-ADA3 and
lexA-ADA2 respectively. Furthermore, GCN5 binds ADA2, and superrepresses
lexA-ADA2. In addition, GCN5 does not bind ADA3, and does not superactivate
or superrepress lexA-ADA3. Together, this suggests that the architecture of the
ADA complex formed in vitro, in which ADA2 acts as a linchpin between ADA3
and GCN5 (Horiuchi, et al., 1995), may also exist in vivo. Moreover, GCN5 can
superrepress lexA-ADA2 in an ada3 deletion strain, suggesting that ADA2 and
GCN5 can associate in vivo in the absence of ADA3.
As a way to address whether the ADA complex exists in vivo, whole cell
yeast extracts were fractionated using conventional and affinity chromotagraphy
in an attempt to purify an ADA complex. In these experiments, ADA2 and ADA3
co-purify using two different methods of purification (N. Silverman, unpublished
results). Here, we have shown that GCN5 shows the same elution profile as
ADA2 and ADA3 for the final stage of one purification procedure (Figure 1,
107
bottom). Additionally, the copurification of GCN5 and ADA3 in the first two
stages of the other fractionation are shown (Figure 1, top). Moreover, ADA2,
ADA3 and GCN5 co-purify through two additional chromatography steps (data
not shown and N. Silverman, unpublished data). This is consistent with a
model in which ADA2, ADA3 and GCN5 are part of a multi-subunit complex in
vivo. The purification of the ADA2 complex is still in progress. Thus, it is
unknown how many other proteins are in the complex with ADA2, ADA3 and
GCN5.
Several large complexes of transcription factors have been purified from
yeast. The products of the SW11, SWI2/SNF2, SW13, SNF5 and SNF6 genes
function as a large multi-subunit complex to mediate histone anti-repression
(Cote, et al., 1994; Hirschhorn, et al., 1992). The products of the SRB genes,
isolated as suppressors of a conditional RNA polymerase II mutant cofractionate
as part of the RNA polymerase holoenzyme (Hengartner, et al., 1995; Kim, et al.,
1994; Koleske, et al., 1992). In addition, several yeast TAF complexes have
been purified (Poon and Weil, 1993; Reese, et al., 1994). One of them supports
Pol III transcription (Poon and Weil, 1993), and the other can mediate Pol II
activated transcription in vitro (Reese, et al., 1994). The purified ADA complex
may also be able to regulate transcirption in vitro.
Finally, a putative human homolog of GCN5from the XREF database has
been identified by sequence similarity (Reeves, et al., 1995). The amount of
sequence similarity is very high over the entire cDNA fragment. Isolation of the
complete cDNA will allow functional studies to be conducted. Additionally,
isolation of a human homolog of ADA2 has been reported (Barlev, et al., 1995).
This indicates that the important role of the ADA2 complex has been conserved
in evolution.
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MATERIALS and METHODS
ADA2 complex purification
In the first fractionation, whole cell extracts were chromatographed on a
Bio-Rex 70 column, followed by stepwise elution in 100mM, 300mM or 600mM
potassium acetate. ADA2 and ADA3 elute in the 600mM fraction. Following
dialysis, this fraction was chromatographed on a DE52 column, which was
eluted in 100mM, 400mM and 600mM potassium acetate. ADA2 and ADA3
both elute in the 600mM fraction. Following dialysis, this fraction was
chromatographed on a Hydroxyapatite column, and was eluted in a potassium
acetate gradient. Again, ADA2 and ADA3 have the same elution profile. ADA2
enriched fractions were pooled, and chromatographed on a Heparin column.
The gradient elution reveals that, yes, ADA2 and ADA3 copurify once again.
The level of ADA2 and ADA3 peaks in fraction 19. To determine if GCN5 is
cofractionating with ADA2 and ADA3, fractions 16, 19 and 22, which cross the
ADA2/ADA3 peak were assayed for GCN5 by Western blot analysis with
aGCN5 protein A purified IgGs.
In the second purification, whole cell yeast extracts from a strain expressing
ADA2 that is tagged with six Histadine residues from its own promoter was
chromatographed over a Bio-Rex70 column, and stepwise eluted with 250mM, 600mM
and 1200mM potassium acetate. ADA2 and ADA3 are retained on theBio-Rex70
column, and elute in the 600mM and 1200mM but not 250mM potassium acetate
elutions. The 600 and 1200 elution fractions were dialyzed, and chromatographed
separately on a nickel beads column to affinity purify ADA2, followed by an elution with
an Imidazole gradient. Both ADA2 and ADA3 are retained on the column by Western
analysis (N. Silverman, unpublished results). Each of these fractions was assayed for
the presence of GCN5 by Western blot analysis using aGCN5 IgGs. The 600Ni and
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standard protocols (Harlow, 1988). Strains were grown in SD rich drop out
medium containing all amino acids except those needed for plasmid selection.
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Chapter 4:
Cloning And Characterization Of ADA5:
A Putative Coactivator That Does Not Copurify With The ADA2 Complex.
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INTRODUCTION
Transcription of RNA polymerase II genes in eukaryotes is highly
complex, and requires many different polypeptides. These include activators
that bind to enhancer/UAS elements, the basal transcription factors that work
through TATA or initiator elements, and transcriptional adaptors/coactivators
that are necessary for activated but not basal transcription. One model
suggests that activation proceeds though direct interactions between activation
domains and basal factors (Lin, 1991; Stringer, et al., 1990; Xiao, et al., 1994).
Basal factor mutants have been identified that cannot support activated
transcription and show decreased binding to activation domains, suggesting
that direct interactions indeed play a role in activation. However, activation
cannot be reconstituted in vitro with basal factors alone and requires the
presence of coactivators (Pugh and Tjian, 1990).
Coactivators have been proposed to function by mediating the interaction
between basal factors and activation domains (Berger, et al., 1990; Kelleher, et
al., 1990; Pugh and Tjian, 1990). Several proteins with coactivator activity have
been shown to bind basal factors and activation domains. These include
PC4/p15 (Ge and Roeder, 1994; Kretzschmar, et al., 1994), CBP (Kwok, et al.,
1994), and the X protein from herpes virus (Haviv, et al., 1995). The TATA
binding protein (TBP) associated proteins (TAFs) form a complex with TBP
capable of responding to sequence specific activators (Dynlacht, et al., 1991).
Different TAF subunits bind to and mediate activation by different classes of
activation domain (Goodrich, et al., 1993; Hoey, et al., 1993; Thut, et al., 1995).
Other coactivators have been isolated genetically in yeast. For example,
the SRB genes were isolated as suppressors of truncations in the conserved
Carboxy terminal Domain (CTD) of RNA polymerase II (Koleske, et al., 1992;
Thompson, et al., 1993) These gene products copurify in a complex called the
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mediator that can bind activators (Hengartner, et al., 1995), and has coactivator
activity (Hengartner, et al., 1995; Kim, et al., 1994). The SRBs are also
members of the RNA polymerase holoenzyme, which can respond to activators
(Kim, et al., 1994; Koleske and Young, 1994). The products of the SWI1,
SWI2/SNF2, SW13, SNF5 and SNF6 genes, identified as positive regulators of
SUC2 and HO transcription (Neigeborn and Carlson, 1984; Stern, et al., 1984),
are part of another coactivator complex that antagonizes histone repression in
vivo and in vitro (Cote, et al., 1994; Hirschhorn, et al., 1992).
The SPT genes were isolated as suppressors of Ty insertions in yeast
promoters (Winston, et al., 1984). The two major classes of these genes act as
regulators of transcription in chromatin and non-chromatin pathways (Winston,
1992). The latter class includes SPT15, which encodes the TATA binding
protein TBP (Eisenmann, et al., 1989; Hahn, et al., 1989), as well as SPT3,
SPT7 and SPT8 (Eisenmann, et al., 1989). Genetic and biochemical evidence
suggests that SPT3, SPT7, SPT8 may act as a complex with SPT15
(Eisenmann, et al., 1994; Eisenmann, et al., 1992; Gansheroff, et al., 1995).
Strains harboring mutations in spt3, spt7, spt8 or sptl5 show reduced
expression of the Ty element, reduced expression of other yeast genes, and a
start site alteration at the Ty locus (Winston, 1992). Thus, in vivo, the putative
SPT3 complex may act to regulate promoter selection by TBP (Winston, 1992).
Other genes important in yeast transcription are ADA2, ADA3 and GCN5,
isolated in a selection for mutants resistant to GAL4-VP16 mediated toxicity
(Berger, et al., 1992; Marcus, et al., 1994). Mutants in these genes relieve
toxicity by reducing the ability of the VP16 activation domain to activate
transcription without altering GAL4-VP16 expression. Moreover, ada2 ada3
and gcn5 mutants all have similar phenotypes including slow growth on
minimal medium, temperature sensitivity, and a reduced ability to support
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activation by certain activation domains in vivo and in vitro (Berger, et al., 1992;
Marcus, et al., 1994; Piia, et al., 1993). In vitro translated ADA2, ADA3 and
GCN5 form a complex (Horiuchi, et al., 1995), and cofractionate from yeast
extracts (N. Silverman, unpublished results, Chapter 3). Genetic evidence also
supports the model that ADA2, ADA3 and GCN5 operate in vivo as a complex
(Marcus, et al., 1994). ADA2 can bind activation domains that are ADA2
dependent, which may determine the specifity for the ADA2 complex (Barlev, et
al., 1995; Silverman, et al., 1994). ADA2 is necessary for a TBP-VP16
interaction in yeast extracts (Barlev, et al., 1995). This supports the model that
the ADA2 complex serves as a physical link to strengthen the interaction
between activation domains and basal factors.
Here we report the cloning and initial characterization of ADA5. ada5
mutants , unlike the other ada mutants, relieve toxicity at least in part by reduced
expression of GAL4-VP16. Furthermore, ada5 mutants have a more severe
slow growth phenotype, and more general transcription defects than the other
ada mutants. The phenotypic differences between ada2 complex mutants and
ada5 mutants suggests that ADA5 is a novel class of genes resistant to GAL4-
VP16. Consistent with this view, GCN5 and ADA5 do not co-fractionate in yeast
extracts. However, ada2ada5 and ada3ada5 double mutants suggest that
ADA5 operates in the same pathway as the ADA2 complex. ADA5 may act as a
transcriptional adaptor because it can bind the VP16 activation domain, and is
identical to SPT20, a gene that may regulate the binding of TBP to promoters.
RESULTS
Properties of the ada5-1 mutant
ada5-1 is a recessive mutant isolated in a screen for mutants resistant to
GAL4-VP16 mediated toxicity that is described elsewhere (Berger, et al., 1992).
118
Whereas multiple alleles of ADA2, ADA3 and GCN5 were isolated, only one
allele of ada5 was isolated (Marcus, et al., 1994). The ada5 mutant grows
slowly on rich medium as well as minimal, which distinguishes it from the other
ada mutants, which only have a pronounced slow growth phenotype on
minimal (Marcus, et al., 1994) and references therein). In tetrad analysis, the
slow growth phenotype segregated 2:2, and co-segregated with resistance to
GAL4-VP16 (data not shown), showing that the slow growth and toxicity
resistance phenotypes are the result of a single mutation.
ADA2, ADA3 and GCN5 mutants survive GAL4-VP16 toxicity by reducing
the ability of GAL4-VP16 to activate transcription, rather than reducing the level
of the toxic protein (Berger, et al., 1992; Marcus, et al., 1994; Piha, et al., 1993).
To determine whether the ada5 mutant relieves toxicity by the same
mechanism, we made protein extracts from wild type and mutant strains
expressing a less toxic derivative of GAL4-VP16, (Phe 442-Ala, designated
GAL4-VP16FA (Berger, et al., 1992)) from a low copy plasmid. These extracts
were mixed with a radiolabled GAL4 binding site oligonucleotide and
electrophoresed. As shown in Figure 1, there is less of the GAL4-VP16 specific
complex in the ada5 mutant strain (lanes 2,3 vs. lanes 4-6). Other, background
bands, are identical in the mutant and wildtype extracts, showing these
differences are specific to GAL4-VP16 expression. Thus, the expression or
stability of GAL4-VP16 FA is somewhat reduced in mutant cells, which may
explain why ada5-1 mutants are resistant to toxicity.
However, a slight reduction in GAL4-VP16 expression from the ADH1
promoter on a 2p (high copy) may not be sufficient to relieve toxicity because
ADH1 driven GAL4-VP16 on an ARS-CEN (low copy) plasmid is toxic to
wildtype cells. Moreover, lower expression of GAL4-VP16 does not preclude
the possibility that ADA5 functions as a coactivator to mediate activation by the
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Figure 1 (Following page). Levels of GAL4-VP16 are reduced in the ada5-1
mutant strain. BP1, a wild type strain and GMy37p (BP1 ada5-1) were
transformed with pGAL4-VP16FA a/c, an ARS-CEN plasmid that expresses
GAL4-VP16 Phe442-Ala (GAL4-VP16FA, a less toxic VP16 mutant) from the
ADH1 promoter. Whole cell protein extracts were made, and used to shift a
radiolabled GAL4 oligonucleotide probe (lanes 2-6, labled "Lo"). Extracts were
also prepared from GMy37p expressing GAL4-VP16FA from the ADH1
promoter on a 2p (high copy) plasmid (lanes 7-10, labled "Hi"). Purified
recombinant GAL4-VP16 (Gift of S. Treizenberg) was used as a control in Lane
1 to identify the GAL4-VP16 specific band.
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WT ada5-1
GAL4-VP16FA rotein LO LO L L Hi Hi Hi
copy numberLo Lo Lo i Hi
Lane 1 2 3 4 5 6 7 8 9 10
GAL4-VP 16FA - *
VP16 and/or other activation domains. Therefore, we attempted to equalize the
levels of GAL4-VP16 in mutant and wildtype cells in order to determine whether
VP16 mediated activation depends on ADA5. To do this, we used a low copy
(ARS-CEN) plasmid to express GAL4-VP16 FA in wildtype cells, and a high
copy (2p) plasmid to express GAL4-VP16FA in ada5 mutant cells. Under these
conditions, GAL4-VP16FA in the mutant cells is equal to or greater than the
level of GAL4-VP16FA expressed in wild type cells (Figure 1, lanes2-3 vs.
lanes7-1 0).
In these conditions, when the level of GAL4-VP16FA is the same in the
mutant and wildtype, we measured the ability of GAL-VP16 FA to activate by
measuring the activity of the 8-galactosidase gene expressed from the GAL1-
10 promoter. As shown in Table 1, there is a two fold difference in activation by
low copy GAL4-VP16FA in wildtype cells and high copy GAL4-VP16FA in the
mutants. (The activity of ARS-CEN GAL4-VP16FA in mutant cells, and 2pGAL4-
VP16FA in mutant cells are included for completeness). We believe that the two
fold reduction in activation by GAL4-VP16FA in ada5 mutants may be
underestimating the requirement by VP16 for ADA5 in activation (see
Discussion).
Cloning, mapping and sequencing of ADA5
ADA5 was cloned by complementation of the slow growth phenotype of
ada5-1 mutant (see Methods). The ADA5 clone has the ability to restore wild
type growth and sensitivity to GAL4-VP16 to the ada5 mutant strain (Figure 2).
To confirm that the clone indeed corresponds to the ADA5 gene, a 1.8 Kb Xbal
fragment from the insert was subcloned into an integrating vector containing the
URA3 gene, and targeted to the ADA5 locus in a wild type strain. The resulting
strain was mated to the ada5-1 strain, the diploid was sporulated, and tetrads
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ada5-1
clone
V16
ADA5 clone
RS425
FIGURE 2. The ADA5 clone complements the ada5-1 mutant for
both growth and toxicity. GMy37p, the ada5-1 mutant strain was
transformed with all pairwise combinations of p3,1 the ADA5 clone(or pCT3 its URA3 vector) and either a 2p high copy plasmid
expressing GAL4-VP16 (GV16) from the strong constituative ADH1
promoter (or pRS425, a LEU2 vector). Transformations were plated
on the same plate, and scored for growth and sensitivity to GAL4-
VP16. Note that wildtype growth and sensitivity to GAL4-VP16
toxicity are restored by the clone.
CT3
pRS4
CT3
GV1(6
were dissected. In all tetrads, two spores grew slowly and were Ura-, and two
spores grew normally and were Ura+. This shows that the ADA5 clone is linked
to the ada5-1 mutant locus.
In order to map ADA5to the yeast physical map, the 1.8 Kb Xbal
fragment was radiolabled and hybridized to a phage grid representing over
90% of the yeast genome (see methods). Two overlapping clones were
identified, showing that ADA5 maps to the right arm of Chromosome XV. There
were no genes previously mapped in this region of the genome. Therefore,
ADA5 was further subcloned and sequenced (see Methods).
The sequence of ADA5 is shown in Figure 3. The gene encodes a novel
protein with 604 amino acids and a predicted molecular weight of 68Kd. The
ADA5 protein contains two glutamine rich regions, several Ser/Thr rich regions,
a proline rich region, and an acidic region (not shown). As a final confirmation
that the open reading frame we identified corresponds to ADA5, the open
reading frame was amplified using the Polymerase Chain Reaction (PCR) and
placed under the control of the ADH1 promoter (see Methods). This plasmid
complements the ada5-1 mutation as well as the genomic clone.
Characterization of ADA5 deletion mutants
ada5 deletion mutants (ada5A) were constructed by homologous
recombination as described in the methods. The ADA5 gene is not essential,
but deletion mutants grow more slowly than the ada5-1 mutant (Figure 4). It
would be unlikely that a null mutant of ada5 could be isolated in the toxicity
screen due to its extremely poor growth, which could explain why only one,
presumably hypomorphic, allele of ada5 was isolated. The ada5A allele,
however, is resistant to toxicity (data not shown). In addition, ada5A strains are
inositol auxotrophs and temperature sensitive (data not shown).
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Figure 3 (Following three pages). The DNA and protein sequence of the ADA5.
The sequence of ADA5 was determined as described in the Methods. The
sequence of ADA5 contains an open reading frame of 604 amino acids, with a
predicted molecular weight of 68Kd. The Figure was prepared using DNA
Strider.
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Figure 4. The ada5 deletion mutant strain grows more slowly than
the ada5-1 mutant strain. GMy30, an ada5 deletion mutant strain
(Aada5), GMy37p, an ada5-1 strain and BWG1-7a the isogenic
wildtype strain were streaked on rich (YPD) medium. Growth was
scored after two days (A) and three days (B).
Amino acids 1-437 of ADA5 can complement a ada5A mutant for
growth but not toxicity
In the process of subcloning ADA5, we discovered that portions of the
ADA5 coding sequence could be deleted without loss, or with only partial loss
of the ability to complement an ada5 mutant strain. (See Materials and Methods
for more details). As shown in Figure 5, ADA5437, the first 437 amino acids of
ADA5 (with a 22 amino acid tail from vector sequence) can complement a
ada5, strain for growth on rich medium, but can only partially complement for
growth on minimal medium. Furthermore, ADA54 7 strains are resistant to
GAL4-VP16 (Figure 6). This is the first time that the growth and toxicity
phenotypes have been separated in an ADA gene.
In order to determine whether ADA5437 strains are resistant to toxicity by
lowering the level of GAL4-VP16 in the cell we compared the levels of ARS-
CEN GAL4-VP16FA in a ada5A strain, an ada5437 strain, and a wildtype strain
by gel shift analysis. As shown in Figure 7, the level of ARS-CEN GAL4-
VP16FA is lower in ada5437 strain than the wildtype strain, but higher than the
level of protein in the ada5 deletion strain. As is the case with the ada5-1 allele,
we cannot rule out the possibility that lower expression of the toxic chimera
contributes to the resistance of ada5437 mutants.
ADA5 deletion strains show broad activation defects in vivo.
The lower expression of GAL4-VP16FA in ada5 mutants may indicate
that ADA5 is regulating the ADH1 promoter. To determine whether the ADH1
promoter or other yeast promoters require ADA5 for activation, we introduced 8-
galactosidase reporter plasmids under the control of eight different yeast UAS
sequences into the wild type, the ada5-1 mutant strain, and the ada5 deletion
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ADA5 (1-437)
ADA5 (1-437)
Figure 5. The first 437 amino acids of ADA5 are sufficient to
complement the slow growth phenotype of Aada5 on rich medium,
but only partially complement on minimal medium. A+B) GMy30, a
A ada5 mutant was transformed with the full length ADA5 clone, the
ADA5 437 fragment (containting the first 437 amino acids of ADA5),
or a vector control. Transformants were restreaked on either drop
out medium and scored after two days (A), or restreaked on minimal
medium and scored after three days (B).
ADA5 vector
ADA5 vector
ADA5
GAL4-VP16
ADA5 (1-437)
GAL4 -VP 16
ADA5 (1-437)
vector
Figure 6. ADA5437 does not restore resistance to GAL4-VP16 to an
ada5 deletion strain. GMy30 complemented by full length ADA5 orADA5 437 were transformed with pSB201, a 2p plasmid expressingGAL4-VP16 from the ADH1 promoter, or a vector control and plated
on drop out medium. Transformation plates were scored for growth
after three days.
ADA5
vector
ADA5
(1-604)
GAL4-VP16FA
Lane
GAL4 -VP 16FA - 0-
- +
1 2
ADA5
(1-437)
I+
4
AADA5
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Figure 7. Levels of GAL4-VP16 are reduced in the ADA5 437truncation mutant. GMy30 was doubly transformed with pa/cGAL4-
VP16FA as well as pRS316 ADA5, pRS316ADA5 437, or vector.
Protein extracts from these strains, as well as from a strain without
GAL4-VP16FA (lane 1) were used to shift a radiolabled GAL4
oligonucleotide.
strain. The levels of 8-galactosidase were assayed in each strain as a way to
measure activation by these promoters. The results are summarized in Table 1.
The activity of the HIS66 and 14x2 promoters, activated by GCN4, the
ADA2/ADA3/GCN5 dependent activation domain, is reduced 7-10 fold in the
ada5 mutant and deletion strains. This suggests that GCN4 requires ADA5 as
well as the other ADAs to activate. In addition, UAS1 and ADH1 mediated
transcription, which is independent of the other ADAs, is down three fold in the
ada5-1 mutant, and 10 and 5 fold respectively in the ada5 deletion strain. In
addition, transcriptional activation by the HO promoter is down 10 fold in the
mutant and 20 fold in the deletion, and activation by the IN01 promoter is down
over twenty-five fold in the mutant, and is undetectable in the deletion.
Interestingly, the two promoters activated by HAP4 and GAL4, the ADA2
independent activation domains still retain much of their ability to activate in the
ADA5 mutant. The activity of UAS2, which uses the HAP4 activation domain is
unchanged in the mutant, and is only reduced five fold in the deletion.
Similarly, UASGAL mediated transcription is only down three fold in the ada5
deletion.
The activation data correlates with some of the growth properties of the
ada5 mutant and deletion strains. In general the ada5 -1 mutant strain show
less severe defects for both growth and activation than the deletion strain.
Further, the inability to transcribe the INO1 gene is a likely reason for the inosital
auxotrophy. In addition, ada5 strains grow slowly on minimal medium, and
have defects in GCN4 mediated activation. GCN4 regulates the synthesis of
amino acid biosynthetic genes in response to starvation (Hinnebusch, 1985).
Finally, activation by the ADH1 promoter is reduced in ada5-1 and ada5A
strains, which explains the lower levels of GAL4-VP16FA in ada5-1 and ada5A
mutants.
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Table 1 (Following page)
LEGEND: (Top) The wildtype strain BP1 (Piria, et al., 1993) was transformed an
ARS-CEN plasmid expressing GAL4-VP16FA, and GMy37p, the ada5-1 strain
was transformed with a 2p plasmid expressing GAL4-VP16FA. In addition, both
strains were transformed with pLGSD5 a reporter plasmid with the 8-
galactosidase gene under the control of the GAL4 promoter. Activity of the 8-
galactosidase gene averaged from multiple experiments is reported. Bottom:
BWG1-7a the a wildtype strain, ada5-1 mutants and ada5d deletion strains
were transformed with the following 1-galactosidase reporter plasmids:
pLG312AAluXho, which contains theCYC1 UAS1 (Guarente, et al., 1984);
p265UP1, which contains the CYC1 UAS2 (Forsberg and Guarente, 1989);
pHIS66, which contains the HIS4 UAS (Hinnebusch, et al., 1985); p14x2, which
contains two synthetic GCN4 binding sites (Hinnebusch, et al., 1985); pCP8
(Gift of C. Peterson), which contains HO URS1 (-1516 to -901; plNO1 (Scafe, et
al., 1990); pLGSD5 containing the GALl-10 promoter and pCPO, containing
the ADH1 promoter (Santangelo, et al., 1988). Activity of the 1-galactosidase
gene averaged from multiple experiments is reported. Activity of pLGSD5 was
measured after induction with Galactose, and the activity of the IN01 reporter
was assayed after five hours induction in -Ino medium (Scafe, et al., 1990).
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ada5-1 Aada5
a/c GAL4-VP16FA 3429 135 ND
2p GAL4-VP16FA 6538 1734 ND
UAS1 989 282 92
UAS2 347 251 71
HIS66 217 19 23
14x2 20 3 4
HO 206 23 10
IN01 101 4 <1
SD5 9588 ND 3027
3245 1600
WT
ADH1 8948
ADA5 binds to VP16
One way that ADA5 could regulate the activation of these promoters
would be as a transcriptional adaptor that mediates the interaction of activation
domains and basal factors. One prediction of this model is that ADA5 should be
able to bind activation domains. Therefore, we tested whether in vitro translated
ADA5 can bind directly to the VP16 activation domain in GST- VP16 pull down
experiments (see Methods). ADA5 binds the full length VP16 activation domain
containing residues 413-490 (Figure 8 Lane 1), but does not bind a VP16
mutant (413-456 Phe442-Proline) that cannot activate (Lane 2). The unmutated
N-terminal VP16 activation domain (413-456) also does not bind ADA5 (data
not shown). Another ADA gene, GCN5, does not bind VP16 in this assay (data
not shown), suggesting that theVP16-ADA5 interaction is specific. The specific
ADA5-VP16 interaction suggests that ADA5 may stimulate activation by binding
to activation domains.
Double mutants between ADA5 and other adas
ADA 1 is another ada gene that has been shown to regulate the ADH1
and UAS1 promoters (J. Horiuchi, unpublished results, Berger, et al., 1992).
Furthermore, adal deletion mutants have similar growth properties to ada5
deletion mutants (data not shown), suggesting ADA1 and ADA5 may act as a
complex or in the same pathway in vivo. Therefore, we constructed an
adalada5 double deletion mutant (see Methods). As shown in Figure 9, adal,
ada5 and ada lada5 deletion mutants all have the same slow growth phenotype
on rich medium. This is consistent with the model that ADA5 and ADA1 mediate
activation in the same pathway or as a complex.
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Figure 8 (Following page). ADA5 binds to the VP16 activation domain.
Wildtype or mutant VP16 fused to the glutathione transferase protein were
tested for their ability to interact with ADA5. "GST-VP16" the wildtype VP16
fusion contains the full length VP16 activation domain (residues 413-490).
"GST-VP16FA" contains residues 413-456 phe442-pro. GST-VP16 (Lane 1) or
GST-VP16FA (Lane 2) were incubated with in vitro translated ADA5,
precipitated with Glutathione beads and washed . Samples were eluted with
glutathione, electrophoresed on an SDS PAGE gel, which was dried and
exposed on a phosphoimager screen for two days.
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GST-VP16FP
GST-VP 16
LANE J121
ADA5 -- ~
The growth and activation phenotypes are more general and severe in
ada5 deletion mutants than in ada2, ada3 or gcn5 deletion mutants. This
suggests that ADA5 could be mediating activation by a different mechanism
than the ADA2 complex genes. Moreover, ADA5 and ADA2 both can bind to
the VP16 activation domain, and may have partially redundant functions. If
ADA5 indeed functions in a separate pathway from ADA2 and ADA3, then
ada5ada2 or ada5ada3 double deletion mutants should have a synthetic
phenotype. Surprisingly, Aada2ada54 and Aada3ada5A double deletion
mutants are viable and grow no more slowly than ada5A single mutants on rich
medium (Figure 10 and data not shown). This shows that ADA5 is not solely
responsible for activation in the absence of ADA2 or ADA3, and suggests that
ADA5 may operate in the same pathway. It is not possible to consistently
compare the growth of these strains on minimal medium because they are too
sick.
GCN5 and ADA5 do not co-fractionate over a Bio-Rex 70 column.
ADA2, ADA3 and GCN5 can form a complex in vitro (Horiuchi, et al.,
1995), and copurify from yeast extracts (N. Silverman, unpublished results and
Chapter 3). Furthermore, double deletion mutants in any two of these genes
have slow growth phenotypes no more severe than the single mutant
phenotypes, suggesting these genes operate as a complex in vivo as well
(Marcus, et al., 1994). Given that the growth phenotypes of ada5ada2 and
ada5ada3 double deletion mutants suggests ADA5 may be in the ADA2
complex, we examined whether ADA5 co-purifies with GCN5, a member of the
ADA2 complex.
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Aadal Aada5
pRS316 pADA1
.A.DA1E
RS316
RS315pADA1
pADA5
Figure 9. adal ada5 double deletion mutants have similar growth
properties. GMy40, an ada5 adal double deletion mutant, was
transformed with all pairwise combinations of pRS315ADA5 (or
pRS315 a LEU2 vector) and YCp50ADA1, (or pRS316, a URA3
vector). Transformants were restreaked on drop out medium (rich),
and scored after two days.
pRS 316 pADA
Aada3 Aada5
pRS316 pADA3
pRS316
pRS315
pADA3
pADA5
Figure 10. ada3 ada5 double deletion mutants grow as well as
ada5 deletion mutants. GMy38, an ada5 ada3 double deletion
mutant was transformed with all pairwise combinations of
pRS315ADA5 (or pRS315 a LEU2 vector) and pADA3HHV (or
pRS316, its URA3 vector). Transformants were restreaked on drop
out medium (rich), and scored after three days. Note that the figure
names the plasmids in the strain and not the genotype. Thus, the
transformant with only the ADA5 clone has the growth properties of
an ada3 mutant, and the transformant with only the ADA3 clone has
the properties of the ada5 mutant.
The three elution fractions as well as the starting material and flowthrough
fractions from the Bio-Rex 70 column, the first step in the ADA2 complex
purification, were assayed for ADA5 and GCN5 by Western blot analysis (See
methods for more detail of fractionation). As shown in Figure 11, ADA5 is not
retained on the column and is detected only in the flow-through and starting
material. GCN5, on the other hand, although not detectable in the starting
material, is clearly in the 600 and 1200 mM elution fractions. ADA2 and ADA3
also elute in the 600mM and 1200mM fractions similar to GCN5 (N. Silverman
and LG, unpublished data). Furthermore, ADA5 protein could not be detected
in any of the later fractions where ADA2, ADA3 and GCN5 co-purify (data not
shown).
Because the ADA5 antiserum is more sensitive than the GCN5 antiserum
(data not shown), ADA5 could not be co-fractionating with GCN5 in anything
near an equal stochiometry. Therefore, because ADA5 does not copurify with
GCN5, and because GCN5 co-purifies with ADA2 and ADA3, ADA5 does not
appear to be a member of the ADA complex (hereafter designated the ADA2
complex). In addition, in vitro translated ADA5 failed to coimmunoprecipitate
with cotranslated ADA2, ADA3 or GCN5 (data not shown).
ADA5 is also SPT20
SPT20 is a newly isolated SPT gene that appears to be in the SPT15
(TBP) (Eisenmann, et al., 1989; Hahn, et al., 1989) class of SPT genes (S.
Roberts and F. Winston, personal communication). The other genes in this
class are SPT3, SPT7, and SPT8 (Eisenmann, et al., 1989). spt20 mutants, like
the other spt mutants of this class, have pleiotropic mating, growth and
sporulation defects. Furthermore, transcription of the Ty LTR and other yeast
genes is compromised. The pleiotropic growth and transcription defects in
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WCE FT 250
Lane 1 2 3
*p Ws
600
4
1200
5
ADA5
Ia -m GCN5
Figure 11. ADA5 and GCN5 do not cofractionate over a Bio-Rex70
column. Whole cell yeast extracts were chromotographed on a
Bio-Rex70 column. Proteins were stepwise eluted in 250mM,
600mM and 1200mM potassium acetate. 100pg of the whole cell
extract (WCE) and flow through (FT), and 50pg of each elution were
assayed for GCN5 and ADA5 by Western blot analysis. Note the
presence of an abundant yeast protein smaller than ADA5 in the
250mM fraction that gives a non-specific signal.
ada5 deletion mutants suggests that ADA5 could be a spt gene. By sequence
comparison, we determined that SPT20 is the same gene as ADA5 (S. Roberts
and F. Winston, personal communication).
Because ADA5 is also an SPT, it is conceivable that other SPT mutations
would also have an ADA phenotype, i.e. resistance to GAL4-VP16 toxicity.
Therefore, we challenged 11 different spt strains with GAL4-VP16. The results
are summarized in Table 2. As expected, the spt 20 mutant strains are resistant
to GAL4-VP16. In addition, Fy963, an spt7 deletion strain, is completely
resistant to GAL4-VP16, and Fy383 and Fy508, two different spt15 mutant
strains, are somewhat resistant to GAL4-VP16. The remaining spt mutants are
not resistant to toxicity. Interestingly, spt7 and spt15 mutants are phenotypically
similar to spt20 mutants. Although the levels of GAL4-VP16 in these strains has
not been determined, and thus the mechanism of resistance is unknown, it is
nonetheless tantalizing that mutants in TBP are resistant to toxicity (see
Discussion).
DISCUSSION
Here, we report the cloning and initial characterization of ADA5, a novel
ADA gene. Unlike ada2, ada3 and gcn5 mutants, which do not show altered
the expression of the toxic chimera GAL4-VP16 but reduce its ability to activate
(Marcus, et al., 1994) and references therein, GAL4-VP16 expression is lower in
ada5 mutants. Furthermore, because the levels of GAL4-VP16 are lower in
ada5 mutants, it is difficult to determine whether the VP16 activation domain
requires ADA5 in order to activate. However, by expressing GAL4-VP16FA, a
less toxic VP16 mutant, from a low copy plasmid in wt cells and a high copy
plasmid in mutant cells, the level of GAL4-VP16 is roughly equivalent in the two
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Table 2. Most spt mutants are not resistant to GAL4-VP16 toxicity.
SPT GENOTYPE
wt
spt5-194
spt6-140
spt3-401
spt3d203:: TRP1
spt7d::LEU2
spt8-302::LEU2
sptl5-21
sptl5-122
spt20-61
spt20A::URA 3
spt4d::URA3
RESISTANCE TO
GAL4-VP16
+++u+
+ +
~I++++
+++.
.--+
.i
LEGEND. Spt strains were transformed with pGAL4-VP16Ura and matching
pRS426 vector, plated on drop out medium, and scored for growth after two or
three days. Note that L881, Fyl91, Fy210, and Fy247 were transformed with
the LEU2 versions of the VP16 toxicity plasmid and vector, pSB202 and
pRS425 because they are URA3+. Both GAL4-VP16 derivatives are equally
toxic to yeast (G.M., unpublished observation). "-" indicates only pinpoint
colonies form. "++++" indicates the size of the colonies expressing GAL4-VP16
is the same as the vector alone colonies.
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STRAIN
Fy3
Fy363
Fy137
L881
Fy51
FY963
Fy463
Fy383
Fy508
Fy191
Fy21 0
Fy247
strains. In these conditions, GAL4-VP16FA mediated activation is two fold lower
in the ada5-1 strain.
However, this may underestimate the dependence of GAL4-VP1 6WT on
ADA5 for activation in vivo in two ways. First, GAL4-VP16FA is less active than
GAL4-VP16 (Marcus, et al., 1994), which may reflect a loss of the ADA5
interaction. If this is the case, then mutating ada5 would not further depress the
activity of GAL4-VP16FA. This issue could be resolved by comparing the
activity of equal levels of unmutated GAL4-VP16 in mutant and wildtype cells.
Furthermore, the ada5-1 mutant is a hypomorph. Evaluation of the ability of
VP16 to activate in an ada5 deletion strain might show a much larger reduction
in activity. Unfortunately, GAL4-VP16 expression is lower in the deletion strain
than the mutant strain, making it impossible to equalize the levels of GAL4-
VP16 in the wildtype and deletion strains.
In addition, two different hypomorphic ada5 alleles were characterized.
The ada5-1 allele, isolated in the selection does not grow as slowly as the
ada5A mutant, and has less severe activation defects. The ada5437allele can
complement a ada5A strain for growth but is still resistant to GAL4-VP16 toxicity.
We cannot rule out the possibility that instability of the ADA5437 protein is
related to its partial complementation. However, it is unlikely that lower
expression of ADA5 would split the toxicity and growth phenotypes. We favor a
model in which the C-terminal 167 amino acids is a domain of ADA5 that
interacts with a basal factor or activation domain to mediate toxicity. The
remainder of the protein is sufficient to mediate growth on rich medium by
interacting with other basal factors, activation domains or coactivators. In
support of this view, ADA5 and its K. lactis homolog show conservation in four
conserved domains (P. Spellman, G.M. and LG, unpublished data). ada5437
deletes the last conserved domain (data not shown).
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On the basis of five criteria, ADA5 is classified as a novel type of ADA
gene. First, ada5A strains show reduced levels of GAL4-VP16, unlike ada2,
ada3 or gcn5 deletion strains. Second, ada5A mutants grow slowly on rich and
minimal medium. ada2 mutants have only a mild slow growth phenotype on
rich medium. Third, ada5A strains are inosital auxotrophs, whereas Aada2,
Aada3 and Agcn5 mutants are not (J. Horiuchi, unpublished results). Fourth,
promoters that are activate independently of ADA2, such as UAS1 and ADH1
are dependent on ADA5. (In Aada2, Aada3 and Agcn5 mutants, we have used
lexA-GAL4, lexA-HAP4, and lexA -GCN4 fusions to show that the promoter
specificity for ADA2 complex dependence resides in the activation domain and
not in the DNA binding domain or TATA box (Marcus, et al., 1994; Pifia, et al.,
1993). Unfortunately, this test is unavailable in the ada5A strain because the
activity of the ADH1 promoter, which drives expression of the lexA fusions is
lower in ada5 mutants.) Fifth, ADA5 does not co-fractionate with GCN5, which
itself is in a complex with ADA2 and ADA3 (N. Silverman, unpublished data,
Chapter 3).
ADA 1 is in the same class as ADA5 on the basis of three criteria: First,
activation by the UAS1 and ADH1 promoters, which are only ADA5 dependent
are also reduced in adal mutants (J. Horiuchi, unpublished data, Berger, et al.,
1992)). Second, adal, ada5 and adalada5 double deletion strains have the
same growth properties in rich medium. Third, adal deletion mutants have an
spt phenotype (J. Horiuchi, unpublished results). ada2, ada3 and gcn5 mutants
do not have spt phenotypes (S. Roberts and F. Winston, personal
communication; for ADA3 also J. Horiuchi and LG, unpublished data).
Although ADA5 and ADA 1 appear to be a novel class of ADA genes, the
relationship of this class to the ADA2 class of ADAs is somewhat unclear. GCN4
mediated activation which is highly ADA2 dependent (Piia, et al., 1993), is also
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ADA5 dependent. HAP4 and GAL4 mediated activation, which are only mildly
ADA2 dependent (Pifia, et al., 1993), are less ADA5 dependent than most of the
other activators tested (Table 1, activities of UAS2 and SD5). Furthermore, we
have made the genetic argument that ADA2, ADA3 and GCN5 act together in
vivo because double mutants among any pairwise combination of these genes
have a growth phenotype no more severe than the single mutants alone
(Marcus, et al., 1994). If the ADA2 complex and ADA5 work through redundant
and/or independent activation pathways, then we would expect that
Lada2ada5A double mutants would have a more severe growth defect than
either of the single mutants. In contrast, we find that in rich medium, the ada2
ada5 double mutant and the ada3ada5 double mutant grows like an ada5
mutant, which argues that ADA5 is in the same pathway as the ADA2 complex
genes.
Whatever its relationship to the other adas, ADA5 has several
characteristics that suggest it may be a transcriptional adaptor that facilitates or
bridges the interaction between activation domains and basal factors. In vivo,
many promoters require ADA5 for activity. Furthermore, ADA5 binds directly to
the VP16 activation domain. This interaction is specific, because ADA5 did not
bind to variants of VP16 that cannot activate transcription in yeast.
If ADA5 could be associated with other yeast coactivators, the
mechanism it uses to activate might be more apparent. ADA5 does not copurify
with, and cannot be detected in the RNA polymerase holoenzyme (data not
shown) (Koleske and Young, 1994). Furthermore, it cannot be detected in the
SWI/SNF complex (Peterson, et al., 1994), and the Weil lab TAF complex (Poon
and Weil, 1993) (data not shown).
However, ADA5 is identical to SPT20 which based upon its mutant
phenotypes, is in the same class of spt genes as SPT3, SPT7, SPT8 and
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SPT15. These genes regulate start site selection at Ty elements, transcription
of Ty, and transcription of MFA 1. SPT15 encodes the TATA binding protein TBP
(Eisenmann, et al., 1989; Hahn, et al., 1989). SPT3, SPT7 and SPT8 may form
a complex with TBP that regulates promoter selection (Winston, 1992),
(Eisenmann, et al., 1992). SPT20/ADA5 may act in the same pathway or
complex as these SPT genes to regulate promoter selection by TBP (S. Roberts
and F. Winston, personal communication). Moreover, the specificity
determinants for this putative complex may be governed by the interaction of
ADA5/SPT20 with activation domains.
Finally, we have previously argued that toxicity results from the trapping
of basal factors at non-specific sites on DNA to form an "inhibition complex".
According to this model, mutants in basal factors should be able to alter toxicity.
In fact, mutants in TFIIB have been isolated that are hypersensitive to GAL4-
VP16 (R. Knaus and LG, submitted). Furthermore, two different mutants in sptl5
are resistant to GAL4-VP16 toxicity. Although this may be due to lower
expression of the toxic chimera, if not, this supports the "inhibition complex"
model, and supports the contention that TBP is a target of the VP16 activation
domain (Barlev, et al., 1995).
Materials and Methods
Cloning and sequencing of ADA5
GMy37p (mata, ura3-52, leu2, his4, gal4::HIS4, ada5-1) was transformed
with a yeast genomic library on an ARS-CEN plasmid (Thompson, et al., 1993),
and colonies that grew well were selected. From these, we isolated a clone
p3,1 with an 8.5 KB insert that restored wild type growth and sensitivity to GAL4-
VP16 toxicity. After partial digestion with Sau3a, 1-3 Kb fragments from this
clone were isolated from a 1.2% agarose gel, and ligated into pRS316 digested
150
with BamHI to create a subgenomic library. GMy37p was transformed with this
subgenomic library, and large colonies were selected. From this, two
subclones that restored wild type growth and sensitivity to GAL4-VP16 were
isolated, pL1B1 and pL1G1 with 2.2 and 1.8 Kb inserts respectively.
We chose to sequence pL1B1. A unidirectional deletion series from the
Notl site in the pRS316 vector was created using ExoIll and ExoVII enzymes.
Single and double stranded sequencing, using the Sequenase kit (USB), of
deletion subclones from the -20 primer provied sequence on one strand of
ADA5 in L1B1. A partial deletion series from the Kpnl site, and sequence
specific primers were designed to sequence the other strand of pL1B1.
However, the largest open reading frame on pL1 B1 was open at the 5' end,
suggesting the entire ADA5 open reading frame was not complete on the L1B1
subclone. By sequencing the ends of the pL1G1 insert, we learned that pL1G1
is a C-terminal truncation of the same ORF. Using a sequence specific primer,
to sequence the L1G1 subclone, I found that the putative ADA5 ORF,
incomplete on L1B1, continues in L1G1. The remaining ADA5 sequence
derives from L1G1.
ADA5 plasmids
pRS316 ADA5, a subclone with the entire ADA5 coding region, was
created in several stages. The BstXI site in pRS316 (Sikorski and Hieter,
1989)was destroyed by digestion, blunting with T4 polymerase and ligation to
create pRS316-BstXI. A 1.9 Kb. EcoRI fragment containing the first 437 aa of
ADA5 as well as the upstream sequences was cloned into the EcoRI site to
create pRS316 ADA5437a and ADA5437b. (ADA5437a is oriented such that the
BstXI site at the 5'end of ADA5 is proximal to the Sad site in of the polylinker.
ADA5437b is in the other orientation. A 1.9 Kb BstXI -Hindlll fragment from
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pL1 B1, was cloned into the BstXI Hindll sites of pRS316ADA5437a to create
pRS316 ADA5. A 2.6 Kb Xhol Notl fragment from pRS316-ADA5 was cloned
into pRS315 cut with Xhol and Notl to create pRS315-ADA5. pRS306-ADA5
was generated by cloning a 1.8Kb Xbal fragment from p3,1 into pRS306 cut
with Xbal. The ADA5 coding sequence was amplified using PCR with primers
ADA5N and ADA5C. The resulting fragment was digested with Noti, and cloned
into the Notl site of pDB20L to form pDB20L-ADA5.
ADA5 deletion plasmid and strains
The ADA5 deletion plasmid was created in several steps. A 550bp Xhol
blunted BstXI fragment from pL1G1 containing the first 12 codons of ADA5 and
5' flanking sequence was cloned into pBluescript KS+ (Stratagene) cut with
Xhol I and EcoRVto form pBluescript A5BstX. Next, a 2.4 Kb. BamHI Bglll
fragment containing the hisG URA3 cassette from pNKY51 (Alani, et al., 1987)
was cloned into the BamHI site of pBluescript A5BstX. The resulting plasmid,
pADA5nko was chosen because it had the correct orientation of the hisG insert,
such that the BamHI site not destroyed by ligation with Bglll was located farthest
from the BstXI site. Finally, pBluescript ADA5 was cut with Dralll, ligated to a
Notl linker, cut with Notl, and then cut with BstYl. The 400 bp BstYI Notl
fragment containing the C-terminal 136 amino acids and 3' flanking sequence
was cloned into the BamHI Notl site of pADA5nko to form pADA5KO. This
plasmid will delete 437 amino acids from the N-terminus of ADA5, which should
produce a null phenotype.
ADA5 deletion strains were generated by transforming yeast with 10pg of
pADA5KO cut with Xhol Notl. Slow growing Ura+ transformants were tested for
resistance to GAL4-VP16, and mated to previously characterized ada5 mutant
strains of the opposite mating type when available. Strains that were resistant
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to GAL4-VP16 were streaked out on FOA to select strains that looped out the
URA3 sequence. These ura- derivatives were transformed with pRS316-ADA5
to confirm that wild type growth and sensitivitiy to GAL4-VP16 were restored by
the ADA5 clone. In this manner, the ura+ and ura- deletion strains GMy29 and
GMy30 were generated in parent strain BWG1-7a; GMy31 and GMy32 in the
parent strain BP1; and GMy33 and GMy34 in PSy316.
The ada2ada5, the ada3ada5 and the adalada5 double deletion
strains were generated in the following manner. The strain GMy30 containing
the plasmid pDB20L-ADA5, (which contains the ADA5 gene on a plasmid with a
Leu2 marker) was transformed with pADA2KO (Berger, et al., 1992) cut with
BamHI and Xhol, pADA3KO cut with Pvull and BamHI (Marcus, et al., 1994), or
pADA1KO (unpublished gift of J. Horiuchi) with Pvull. ADA 1, ADA2 or ADA3
deletion strains were identified by mating slow growing transformants to Aadal,
Aada2 or Lada3 strains. Strains that failed to complement the cognate ada
deletion strain were grown on FOA to select strains that looped out the URA3
sequence.
The resulting ura- derivatives were grown to saturation in YPD, plated on
YPD plates and replica plated to identify strains that had lost the leu2 plasmid
containing the ADA5 clone. The double mutant genotype of GMy36 (BWG1-7a
L.ada2ada5A), GMy38 (BWG1-7a Aada3ada5A) and GMy40 (BWG1-7a
badalada5Li) was confirmed by transforming these strains with the ADA5 and
the ADA1, ADA2 or ADA3 clones.
ADA5 protein expression, antisera and Western analysis of the Bio-
Rex 70 ADA fractions
The BamHI site at the N-terminus of pL1B1 is in frame with the BamH1
site of pET15b (Novagen). pL1B1 was digested with Draill, ligated with a
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BamHI linker, and then digested with BamHI. The resulting 2.2 Kb fragment
was cloned into the BamHI site of pET15b (Novagen) to form pET15b-ADA5. In
the bacterial strain BL21(Novagen), this plasmid produced large amounts of
insoluble ADA5 protein. The pET15b vector fused a six histadine tag at the N-
terminus of ADA5, which was used for purification on a Ni column (Qiagen).
Lyophylized acrylamide slices containing 400pg ADA5 protein were
resuspended in saline, and injected into two different rabbits (Harlow, 1988).
After several boosts, the antisera from either rabbit can recognize ADA5
expressed in bacteria or yeast. IgG were purified on a protein A column
(Harlow, 1988).
The Bio-Rex70 yeast fractions (gift of Neal Silverman) are described in
Chapter 3. Westerns were performed using using HRP conjugated donkey anti-
rabbit secondary antibody (ECL) according to standard protocols (Harlow,
1988). Westerns performed with ADA5 antisera were incubated with secondary
antibody for two hours, and washed In TBS-Tween no more than three times for
five minutes each after incubation with either the primary or secondary
antibodies.
Gst-VP16 pull down assay
The ADA5 in vitro translation plasmid pCITE2b-ADA5 was generated by
cloning the 2.2Kb BamHI fragment containing the ADA5 coding sequence (and
some 3' sequence) from pET15b-ADA5 into the BamHI site of pCITE2b
(Novagen). In vitro translations were performed as previously described
(Horiuchi, et al., 1995).
Pull down experiments were performed by incubating 10pg GST-VP16 or
10pg GST-VP16456-490 phe442-pro,10pl Sepharose Glutathione beads
(Pharmacia) preblocked in E. coli extract, and 10pl in vitro translated ADA5 in
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200pl S300 1%T Buffer (20mM HEPES pH 7.6, 300mM potassium acetate, 1%
Triton X100, 20%Glycerol), plus E. coli extract to Img/ml. Binding proceeds for
1hr, followed by 4 washes with iml S300 1%T buffer. Samples were eluted
from the beads by 20mM Glutathione in S100 buffer, and electrophoresed on
an SDS PAGE gel. The dried gel was exposed 2 days on a phosphoimager
screen, and evaluated by phosphoimager (Molecular Dynamics).
Strains, Yeast Manipulations, Media, Gel shifts and 8-
galactosidase assays.
All yeast strains are derivatives of BWG1-7a (mata, adel, ura3-52, leu2,
his4) unless otherwise noted. Transformations were by the LiOAc method
(Gietz, et al., 1992) Tetrad analysis and other yeast manipulations were done
using standard techniques(Guthrie and Fink, 1991) B-galactosidase assays
were carried out on yeast extracts made from breaking cells with glass beads
(Rose and Bostein, 1983). The activity of 3-galactosidase is normalized to total
protein. Gel shift analysis was performed as previously described (Berger, et
al., 1992). Slow growth phenotypes of ada mutants were assayed on SD
minimal medium supplemented with amino acids and adenine. Otherwise
strains were grown in SD rich drop out medium containing all amino acids
except those needed for plasmid selection.
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Chapter 5:
The Role of the ADA genes in transcriptional activation
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In Chapter 1, I suggested that coactivators be evaluated by their ability to
stimulate activation in vivo or in vitro, bind activators, and bind basal factors.
The interaction with activators determins specifity. The basal factor interaction
indicates something about the mechanism used by the coactivator to stimulate
activation. The TAF complex is clearly necessary and sufficient for activation in
vitro (Dynlacht, et al., 1991). Its specificity is governed by interactions between
specific TAFs and activation domains (Chen, et al., 1994; Jacq, et al., 1994).
Individual TAFs interact with TBP, TFIIB and TFIIA (Tjian and Maniatis, 1994).
The yeast SWI/SNF complex is an example of a coactivator complex with a
known mechanism (relief of chromatin repression) but with unknown specifity
determinants (Peterson and Tamkum, 1995). Similarly, the SPT3, SPT7 and
SPT8 genes regulate transcription of certain promoters in vivo, perhaps by
regulating promoter selection by TBP (SPT15) (Winston, 1992). Again, the
mechanism for promoter specificity is unknown. These criteria, regulation of
activation, activator specifity and basal factor targets are a useful method with
which to evaluate the ADA genes discussed in this thesis.
Mutants in ADA1, ADA2, ADA3, GCN5 (ADA4) and ADA5 were isolated
in a selection for mutants resistant to overexpression of GAL4-VP16, which is
toxic to yeast. We believe that the mechanism of toxicity is related to the
mechanism of transcriptional activation because mutants that reduce the ability
of VP16 to activate transcription, or reduce the ability of GAL4 to bind DNA,
which also leads to a reduction in activation, lower the toxicity of GAL4-VP16 in
a correlated fashion (Berger, et al., 1992).
ADA mutants fall into two phenotypic classes. ada2, ada3 and gcn5
deletion mutants releave toxicity by reducing the ability of GAL4-VP16 to
activate without changing GAL4-VP16 expression (Berger, et al., 1992; Marcus,
et al., 1994; Piha, et al., 1993). In addition, these mutants are all recessive,
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grow slowly on minimal medium, are temperature sensitive, and importantly, are
unable to support activation in vivo or in vitro by certain activation domains
(Berger, et al., 1992; Marcus, et al., 1994; Pifa, et al., 1993). Genetic and
biochemical evidence suggests that ADA2, ADA3 and GCN5 operate as a
complex (Horiuchi, et al., 1995; Marcus, et al., 1994; Pifa, et al., 1993), see also
Chapter 3 and (Silverman, et al., 1994). In fact, ADA2, ADA3 and GCN5 co-
purify from yeast extracts (N. Silverman, unpublished data, Chapter 3). This
complex has not been purified to homogeneity, and thus at present the number
of proteins in the ADA2 complex is unknown.
ADA1 and ADA5 comprise the other class. adal and ada5 mutants have
more severe and more general slow growth and activation defects than the
ada2 complex mutants (J. Horiuchi, unpublished data, Chapter 4). Moreover,
they survive toxicity in part by lower GAL4-VP16 expression, and have an spt-
phenotype (J. Horiuchi, unpublished data, Chapter 4). Finally, ada5 mutants
are Ino-, and does not co-purify with the ADA2 complex, which argues that it
indeed operates by a different mechanism than the ADA2 complex genes
(Chapter 4).
The ADA2 complex genes are required for activation by certain actiators
in vivo and in vitro, and are thus considered coactivators (Berger, et al., 1992;
Marcus, et al., 1994; Piia, et al., 1993). The GCN4, HAP4 and GAL4 activation
domains when fused to a common DNA binding domain show differential
requirements for the ADA2 complex genes in vivo, showing that the specifity for
the ADA2 complex can be determined by the activation domain per se (Marcus,
et al., 1994; Pifia, et al., 1993). In fact, the specificity for the ADA2 complex may
be determined by the binding of activation domains to ADA2. ADA2 can bind to
the GCN4 activation domain and VP16 activation domains, which are ADA2
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dependant (Barlev, et al., 1995; Silverman, et al., 1994), but not to the HAP4
activation domain which is ADA2 independent (Barlev, et al., 1995).
Two different basal factor targets of the ADA2 complex have been
proposed. GST-VP16 can retain TBP from wild type yeast nuclear extracts but
not from ada2 extracts, suggesting TBP may be a target of ADA2 mediated
activation (Barlev, et al., 1995). Alternatively, members of the ADA2 complex
have been shown to interact genetically and biochemically with the CTD of
RPB1, the largest subunit of RNA polymerase II (N. Silverman, unpublished
data). ADA2 and ADA3 are also sub-stochiometric components of the
holoenzyme. This argues that the CTD may also be a target of the ADA2
complex.
The activity of the TAF complex is in part mediated by contacts between
individual subunits and different activators or components of the basal
transcription machinery (Tjian and Maniatis, 1994). The ADA2 complex may
operate in an analagous manner. ADA2 directly contacts activators, but only
indirectly interacts with TBP (Barlev, et al., 1995). The TBP interaction may be
mediated by another member of the ADA2 complex. Moreover, ADA2 does not
directly bind the CTD suggesting that another component of the ADA2 complex
is binding the CTD. Clearly, it is the complex as a whole that mediates the
activation domain basal factor interactions.
Additionally, ADA2 has a Cys rich domain that is found in other
coactivators (Arany, et al., 1994). This domain is within a 133 amino acid
fragment of CBP that binds TFIIB, and may mediate this interaction (Kwok, et al.,
1994). Similarly, GCN5 has a bromodomain, another domain present in many
coactivators including TAF250, SW12, SPT7, GCN5, Brahma, and the CBP/p300
class of proteins (Eckner, et al., 1994; Kennison, 1993). . A GCN5 mutant
missing the bromodomain shows reduced growth and less GCN4 mediated
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activation, indicating that the bromodomain is important for the activity of the
ADA2 complex. Although the function of the Cys domain and the bromodomain
are unknown, each may mediate one of many connections between the ADA2
complex and activators or basal factors.
Although not as well characterized as the ADA2 complex genes, ADA5
and ADA1 are putative adapters because of the general activation defects in
ada5 and adal mutants (J. Horiuchi, unpublished data, Chapter 4).
Unfortunately, the lexA activation domain fusions cannot be used to evaluate
whether activation domains can determine ADA5 specifity because the ADH
promoter used to express the lexA fusions is itself regulated by ADA5 (Chapter
4). However, ADA5 binds to the VP16 activation domain, suggesting that
specifity for this class of ADAs may be determined by activator-ADA5
interactions (Chapter 4).
Somewhat paradoxically, ADA1 is phenotypically a member of the ADA5
class, but co-purifies with the ADA2 complex (N. Silverman, J. Horiuchi,
unpublished data). ADA1 can be also detected in the flowthrough fraction of the
Bio-Rex 70 column along with ADA5 (N. Silverman, J. Horiuchi, unpublished
data) None of the other ADA proteins can be detected in the Bio-Rex 70
flowthrough. This suggests that ADA1 is not exclusively associated with the
ADA2 complex. It may be an abundant protein that happens to be in the
flowthrough with ADA5, or based upon common mutant phenotypes, it may be
part of a theoretical second complex with ADA5. In the second complex model,
ADA1 may be playing a role mediating the interaction between ADA5 and the
ADA2 complex. Alternatively, under other conditions, ADA5 may also be a
member of the ADA2 complex. Composition of the RNA polymerase
holoenzyme and TFIID complexes can varry with preparation conditions
(Koleske and Young, 1995; Verrijzer, et al., 1994).
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Furthermore, although ADA5 does not cofractionate with the ADA2
complex, it may work in the same pathway. ada2ada5 and ada3ada5 double
deletion mutants have the growth phenotype of an ada5 deletion mutant, which
argues that ADA5 indeed works in the same pathway as the other ada genes
(Chapter 4). Furthermore, GCN4 mediated activation is highly dependent on
both ADA2 and ADA5, whereas GAL4 and HAP4 mediated activation are
independent of ADA2 and less dependent on ADA5 than any of the other
reporters examined (Chapter 4). Whether or not the ADA2 complex works in the
same pathway as ADA5 and ADA1, all of the ADA genes are coactivators for
several yeast promoters.
The importance of the ADA genes in vivo is demonstrated by the isolation
of ada mutations in several diverse genetic selections. For example, ADA3 was
also isolated as NGG1, a negative regulator of GAL4 activity in the absence of
GAL80 in glucose (Brandl, et al., ). Negative regulation may be an indirect
consequence of ADA3 dependent expression of a repressor, or an indirect
effect of promoter competition between ADA dependent and independent
activators. Alternatively, ADA3, and perhaps the other ADA genes may in fact
be negative regulators of some loci. GAL 11, a putative coactivator and member
of the holoenzyme is both a positive and negative regulator of transcription
(Fassler and Winston, 1989).
In addition, the SWI7, SWI8 and SWI9 genes are identical to ADA2,
ADA3 and GCN5 (K. Pollard and C. Peterson, personal communication).
Mutations in these SWI genes were isolated in a genetic screen for mutants that
do not activate an Ho lacZ reporter gene (Breeden and Nasmyth, 1987). The
relationship of ADA2, ADA3 and GCN5 to the SWI genes that comprise the
SNF/SWI complex and regulate transcription through chromatin is unclear.
Activation by three promoters regulated by the other SNF/SWI genes, IN01,
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SUC2 and HO is reduced in swi7, swi8 or swi9 mutants (K. Pollard and C.
Peterson, personal communication).
However, unlike the other swi/snf mutants, strains carrying swi7, swi8
and swi9 mutants are Inositol prototrophs. Furthermore, the ADA2, ADA3 and
GCN5 proteins are not part of the SWI/SNF complex by Western blot analysis,
although the complex is less stable in swi8 (ada3) mutants (K. Pollard and C.
Peterson, personal communication). Finally, deletion mutants in ada2 can be
suppressed by mutants in TFIIB, suggesting that ADA2 activates transcription in
a chromatin independent manner (R. Knaus and LG, unpublished data). At
present, it is unclear whether the ADA complex "touches" and coordinates
activation with the SWI complex in vivo, or whether the ADA genes are simply
coactivators for an activator such as SW15 that regulates HO transcription.
Whatever the relationship between the SWI complex and the ADA complex, the
isolation of mutants in ada2, ada3 and gcn5 in a screen for regulators of a yeast
promoter underscores the importance of the ADA2 complex genes in the yeast
life cycle.
As its name implies, GCN5 was originally isolated in a selection for
mutants sensitive to 3-aminotriazole, which mimics Histadine starvation
(Hinnebusch and Fink, 1983; Penn, et al., 1983). gcn5 mutants, unlike the other
gcn mutants does not regulate the protein level of the transcriptional activator
GCN4, but rather its ability to activate transcription (Georgakopoulos and
Thireos, 1992). Thus, it had been proposed to be a coactivator for GCN4
(Georgakopoulos and Thireos, 1992).
ADA5 is identical to SPT20, a newly identified member of the SPT3,
SPT7, SPT8 and SPT15 class of Ty suppressors (S. Robberts and F. Winston,
personal communication; Chapter 4). Mutations in any of these SPT genes
have similar pleiotropic growth and transcription phenotypes (Eisenmann, et al.,
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1989). Furthermore, these spt mutants can alter the choice of promoter
selection by SPT15(TBP) without changing the DNA binding properties of TBP
in vitro (Eisenmann, et al., 1992). Based on their similar mutant phenotypes,
and genetic and physical interactions among some members of this group,
SPT3, SPT7, SPT8, SPT15 may act as a complex (Eisenmann, et al., 1994;
Eisenmann, et al., 1992; Winston, 1992). SPT20/ADA5 may act in the same
pathway or complex as these SPT genes to regulate promoter selection by TBP
(S. Robberts and F. Winston, personal communication). Moreover, the
specificity of this putative complex may be determined by the interaction of
ADA5/SPT20 with activation domains.
Finally, homologs of ADA genes have been found in other eukaryotes,
suggesting that the function of the complex is conserved throughout evolution.
Homologs for the ADA2 and ADA5 genes have been isolated from the yeast K.
lactis (P. Spellman and LG unpublished data); for ADA2 in S. pombe (P.
Spellman, N. Silverman and LG, unpublished data); and for ADA2 and GCN5
from humans (Barlev, et al., 1995), Chapter 3). Other coactivators have been
conserved from yeast to humans as well, including SNF2 and the TAFs
(Carlson and Laurent, 1994; Goodrich and Tjian, 1994). Given the important
role transcription factors and other coactivators such as Brahma and
CCG1(TAF250) play in growth, cell cycle regulation and development in
Metazoans (Tamkun, et al., 1992; Wang and Tjian, 1994), it is likely that the
ADA homologs play decisive roles as well.
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APPENDIX I:
Isolation Of Strains Resistant To GAL4-VP16 toxicity
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In Chapter 2, I described a selection for mutants resistant to GAL4-VP16 toxicity
in the strain BP1. A number of alleles of ADA 1, ADA2 and ADA3 were isolated
in addition to the alleles of the new genes GCN5 and ADAS. In addition, a
putative clone for the strain EMS3 from the original mutagenesis was obtained
by complementation of its slow growth phenotype. Its ability to complement
toxicity resistance has not been tested. Furthermore , several strains resistant to
toxicity have not been named or cloned. Table I contains a listing of all of the
ADA mutant strains isolated in this selection.
There are several important characteristics of these strains:
Strain 36n is fully resistant to GAL4-VP16, grows slowly, but does not
express GAL4-VP16, as analyzed by Gel shift analysis (data not shown).
Because of this, it was not studied further.
Strain 44b is resistant, but does not grow slowly. Therefore it has been
very hard to clone. I have not checked the level of GAL4-VP16 by gel shift, and I
have not checked whether any of the ADA clones can restore sensitivity to
GAL4-VP16.
Strain 42d has a dominant slow growth phenotype, but by mating it is
recessive for GAL4-VP16 resistance. I did not check whether the slow growth
co-segregated with the toxicity resistance. I attempted to clone this mutation in
this strain, and a resistant segregant from tetrad analysis, but failed (data not
shown).
Strain 35n is very resistant, but reverts or gets suppressors at a fairly high
rate. To work with this strain, get fresh stocks from the perm regularly.
Strain 32s is sterile. It grows slowly, and is not complemented by the
ADA1, ADA2 or ADA3 clones. Levels of GAL4-VP16 were not checked.
Strain 48o, gcn5-3 is rho-.
EMS3 was identified in the original Berger selection. A putative clone
has been identified. 20 different clones with related inserts were identified, that
complement the slow growth phenotype of EMS3. They have not been checked
for the ability to restore sensitivity to GAL4-VP16.
The same selection was also carried out in the strain PSY316. 9x108
cells were mutagenized to 50-60% lethality, and transformed with GAL4-VP16.
One hundred eighteen colonies were picked and mated to BP1, a strain of the
opposite mating type, selecting for the GAL4-VP16 plasmid. 71 diploid strains
were able to grow with the plasmid, showing that the mutation conferring
resistance was dominant or plasmid linked. These were not studied further. 10
strains did not mate. Of these, only three were resistant upon retransformation.
These were not studied further. 37 strains were able to mate, but the resulting
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diploid did not grow in the presence of GAL4-VP16, suggesting the mutation
giving resistance to GAL4-VP16 is recessive. These strains were mated to
ada 1, ada2 and ada3 mutant tester strains. The diploids were tested for slow
growth and/or resistance to GAL4-VP16. The results are summarized on
TABLE 2.
There were several interesting results of note:
P8f does not grow when mated to the ADA 1 or ADA3 tester strain.
Transformation with the clones shows it to be an ADA 1 allele. Thus, this strain
is an unlinked non-complementer with ada3-1.
All of the strains that are unknown were originally classified as ADA3
alleles, because they grow slowly when mated to ada3-1. However, their
growth is not improved by the ADA3 clone, suggesting that they are not ADA3
alleles, but rather unlinked non-complementers with ada3-1.
P13q was first classified as an ada3 allele. Later, it was classified as a
new gene, and later still it was shown by T. Oheler to be an ada5 allele. This
allele of ada5 shows unlinked non-complementation with ada3-1. This has not
been systematically investigated, and should be considered a preliminary
finding.
The unknown strains have not been tested with the GCN5 or ADA5
clones. These were isolated after these strains were exiled to the freezer.
These strains have not been analyzed by tetrad analysis, and may have
multiple mutations. In addition, they have not been assayed for the presence of
GAL4-VP16 by gel shift analysis. Three strains are sterile, and retransform for
resistance to toxicity (Table 2).
In conclusion, there are additional mutant strains resistant to GAL4-VP16
that have not been cloned or classified. These may also have mutations in ADA
genes that may be members of the ADA2 complex, or may work in the same
pathway as ADA5.
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TABLE 1. Isolation Of Mutants Resistant To GAL4-VP16
Mediated Toxicity In BP1.
STRAIN
B44a
B481
B48n
B36u
B44h
B33h
B331
B37b
B43b
B44d
B34q
B42c
B37o
B36i
B37g
B44i
B45h
B33u
B28g
B25a
B41g
B36u
B43i
B35s
B36r
B47c
B36x
B48o
B37p
B35n
B36o
B42d
B36n
B44s
EMS3
B32s
ALLELE
ada 1-20
ada1-21
adal-22
ada 1-23
ada 1-24
ada2-3
ada2-4
ada2-5
ada2-6
ada2- 7
ada2-8
ada2-9
ada2- 10
ada3-2
ada3-3
ada3-4
ada3-5
ada3-6
ada3-7
ada3-8
ada3-9
ada3-10
ada3-11
ada3-12
ada3-13
gcn5-1
gcn5-2
gcn5-3
ada5-1
NEW GENE
NEW GENE
NEW GENE
NEW GENE
NEW GENE
NEW GENE
NEW GENE
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CRITERIA
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
mating
clone
clone
clone
clone
clone
clone
ADA clones
ADA clones
ADA clones
ADA clones
ADA clones
ADA clones
ADA clones
TABLE 2. Isolation Of Mutants Resistant To GAL4-VP16
Mediated Toxicity In PSy316.
STRAIN
P121
P8f
P4b
P13s
P6k
P7a
P11h
P11i
Pill
P12c
P12i
P13e
P13v
P18a
P19a
P19d
P6e
P6o
P6P
P7r
P1 0e
P13o
P13u
P13q
P7g
P7n
P7P
P8x
P8y
P11b
P12b
P12j
P13m
P19e
P6m
P11f
P11k
P4P
P20b
Pllg
P12f
GENOTYPE
ada l--25
ada 1-26
ada2-11
ada2-12
ada2-13
ada3-14
ada3-15
ada3-16
ada3-17
ada3-18
ada3-19
ada3-20
ada3-21
ada3-22
ada3-23
ada3-24
ada3-25
ada3-26
ada3-27
ada3-28
ada3-29
ada3-30
ada3-31
ada5-2
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
unknown
not tested
not tested
not tested
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CRITERIA
mating
mating
mating
mating
mating
mating
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
mating and
mating and
mating and
mating and
mating and
mating and
mating and
mating and
mating and
mating and
mating and
sterile
sterile
sterile
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
clone
